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             “If it is to be, it is up to me.”  
             ~Wordsworth 
 
  
ABSTRACT 
Polymyositis and dermatomyositis are chronic, inflammatory disorders characterized 
by muscle weakness, low muscle endurance and by inflammation in skeletal muscle 
tissues. The pathogenesis is not completely understood and several mechanisms are 
believed to be involved. Conventional immunosuppressive treatment for patients is 
primarily with glucocorticoids in combination with another immune-modulating drug. 
Although most patients respond to the treatment to some degree, persisting muscle 
weakness as well as continued presence of muscle tissue inflammation is often evident. 
  The main aim was to investigate different pathways that may play a role 
in the disease pathogenesis and contribute to the muscle weakness in patients with 
polymyositis and dermatomyositis. We wanted to determine whether these mechanisms 
were associated with clinical outcome and if immunosuppressive treatment could alter 
the processes. Studies were thus performed by characterizing muscle tissue samples 
from patients before and after immunosuppressive treatment, and through comparison 
with samples from healthy individuals. We also collected in vivo samples from 
quadriceps muscles by microdialysis before and after exercise in both patients and 
healthy individuals. 
 Some novel observations were made. Firstly, we determined that the pro-
inflammatory cytokine interleukin (IL) 15 and the IL-15 receptor alpha (IL-15Rα) were 
over-expressed in muscle tissues from the patients compared to in healthy individuals. 
Immunosuppressive treatment had no effect on IL-15 expression in 1/3 of the patients 
along with a poorer functional outcome. Secondly, we investigated the prostaglandin 
(PG) E2 and leukotriene (LT) B4 pathways. Here we found that PGE2 pathway is up-
regulated in muscle tissue from patients with polymyositis or dermatomyositis 
compared to healthy individuals. A higher expression of cyclooxygenase (COX) 1, 
COX-2 and microsomal PGE synthase (mPGES)-1 in the patients was apparent and 
while COX-2 was down-regulated by treatment, COX-1 and mPGES-1 levels remained 
high. LTB4 pathway was also found to be active in patients and the expression of both 
5-lipoxygenase (5-LO) and the LTB4 receptor 1 (BLT1) were higher compared to in 
healthy individuals. 5-LO activating protein (FLAP), was highly expressed in a 
subgroup of patients who did not respond to immunosuppressive treatment. These 
results may suggest an involvement of PGE2 and LTB4 in vascular permeability and 
chemotaxis for infiltrating immune cells, but perhaps also to serve a purpose in skeletal 
muscle regeneration in patients with polymyositis and dermatomyositis. Lastly, we 
could report that patients with newly diagnosed polymyositis or dermatomyositis did 
not display a low proportion of oxidative type I muscle fibers typically seen in muscle 
tissue of patients in a chronic state of disease. This finding implies that the proportion 
of oxidative fibers does not contribute to the low muscle endurance, at least not in early 
polymyositis and dermatomyositis.  
  The conclusions drawn from this thesis are that several mechanisms may 
contribute to the muscle weakness in different subgroups of polymyositis and 
dermatomyositis patients. New pathways discovered in this thesis include IL-15 and the 
eicosanoids PGE2 and LTB4, but the fiber type composition in the muscle tissue might 
play a lesser role, at least in early disease. The mechanisms identified could provide a 
basis for further studies and possibly new therapies. 
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3 POLYMYOSITIS  & DERMATOMYOSITIS 
 
Polymyositis and dermatomyositis, here also defined as myositis, belong to the 
idiopathic inflammatory myopathies (IIM). Their pathogenesis is not fully understood 
but both genetic susceptibility as well as environmental factors have been implicated to 
play a role in disease development [1, 2]. Polymyositis and dermatomyositis are rare 
diseases, characterized by muscle inflammation and proximal muscle weakness with a 
reported incidence of 1/100,000 cases per year, being more common in women than in 
men [3].  
 
Polymyositis and dermatomyositis are heterogeneous disorders and the classification 
and diagnostic criteria proposed by Boham and Peters 1975 is used in routine practice 
[4, 5]. The use of the additional information derived from the autoantibody profile in 
myositis patients can provide indications of clinical subtypes in disease progress and 
treatment responses [6]. The clinical features develop slowly over time, resulting in 
weakness mainly affecting proximal muscles, shoulder and pelvic girdle muscle being 
most severely affected. Weakness in neck muscles is quite common whereas muscle 
pain is rarely experienced [3]. Extra muscular organ manifestations are evident as lung 
[7, 8] and heart involvement [9, 10] and cancer association [11-13]. Skin rash is one of 
the diagnostic criteria in dermatomyositis . The cutaneous features in dermatomyositis 
appear as rashes over the knuckles called Gottron’s papules/signs, heliotrope rash on 
the upper eyelids and ‘mechanics hands’ (thick, cracked skin at the finger tips) [14].  
 
With muscle being the target organ of this systemic inflammation, the pathological 
signs within the muscle tissue in the patients include expression of inflammatory 
molecules involved in antigen presentation, immune cells, and cytokines but also signs 
of muscle degeneration and regeneration. The inflammation and tissue remodeling is 
ongoing in both the affected muscle groups as well as in the non-symptomatic muscles 
[15]. There are patients with little or no signs of tissue inflammation even with a 
pronounced muscle weakness, indicating that different mechanisms can be the cause of 
the disabled function [16]. The muscle fiber often express major histocompatibility 
complex (MHC) class I [17] and therefore have the potential to present antigens to 
infiltrating T cells. MHC class I may have the ability to mediate muscle damage [18] 
and mice overexpressing MHC class I in muscle fibers have less capacity of force 
generation compared to normal mice [19]. Abnormalities in the vascularity are 
displayed as activated endothelial cells and thickening vessel walls [20, 21]. 
Interspersed adipose tissue within the muscle fascicles can also be seen. 
 
Aside from a triggered immune response, during more recent years hypotheses of non-
immune mechanisms have arisen to explain the pathophysiology leading to muscle 
weakness. Among the theories investigated is endoplasmic reticulum (ER) stress [18, 
22]  that may be induced by MHC class I molecules expression on the muscle fibers 
and hypoxia [23-26]. 
 
The first-line drug treatment in myositis is high dose glucocorticoids, slowly tapered 
over time [27, 28]. Although most patients improve to some extent in response to 
immunosuppressive treatment, many patients experience persistent weakness and some 
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patients do not respond at all. Furthermore, many patients suffer from the steroid side-
effects of weight gain, water retention, hyperglycemia and reduced muscle and bone 
mass [29].  Although some pathways have been discovered from the myositis research, 
there are still gaps in our understanding of what causes muscle weakness in 
polymyositis and dermatomyositis and whether it is the same cause triggering the 
weakness in an early state of disease as in the chronic, treated phase.  
 
 
 
Figure 1. Different influences on skeletal muscle of patients with Polymyositis and dermatomyositis that 
will be discussed in this thesis. Parts of the picture are provided by courtesy of Servier. 
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4 INFLAMMATION 
 
The immune response is composed of the innate and adaptive immune system, serving 
to defend the body against pathogens. In brief, the innate response is a rapid, non-
specific defense where pathogen associated molecular patterns (PAMPs) or damage- 
associated molecular patterns (DAMPs) exposed on the invading pathogen are 
recognized and phagocytized by macrophages, dendritic cells (DCs) or neutrophils. The 
adaptive immune response provides a specific, immunological memory, through the 
recruitment of the effector cells; T and B lymphocytes with the DCs as the major link 
between innate and the adaptive immunity. In the adaptive immune response, antigen 
presenting cells expose non-self epitopes/antigens via MHC molecules to the T cell 
receptor (TCR). There are two major types of T cells, the CD8
+ 
cytotoxic T cells that 
recognize antigens presented on MHC class I molecules and CD4
+
 T helper cells that 
through antigen recognition mediated by MHC class II molecules are able to recruit 
myeloid cells to sites of inflammation, produce cytokines and chemokines, induce 
macrophage activity and antibody production by B cells. Another T cell subgroup is the 
regulatory T cells (Treg) that maintain immune tolerance to self and prevents the 
development of autoimmune diseases. Under normal conditions the resolution of 
inflammation is actively initiated and failure to do so results in chronic inflammation.  
 
 
4.1 NUCLEAR FACTOR KAPPA B 
The transcription factor nuclear factor kappa B (NFκB) is a regulator involved in a 
number of transcriptional programs important to the immune system, epithelium and 
skeletal muscle. NFκB regulates cell survival, proliferation and differentiation for 
maintenance but also in pathological conditions [30].  NFκB exists in the cytoplasm in 
a complex with inhibitory IκB proteins. Upon activation, IκB protein is degraded and 
NFκB is translocated into the cell nucleus where it can modulate gene expression. 
NFκB is largely responsible for the transcription of pro-inflammatory cytokines and 
chemokines. Early NFκB activation of tumor necrosis factor alpha (TNF cytokine 
production then leads to further NFκB induction. Another early target is activation of 
vascular endothelial cells regulating the transmigration of immune cells into the tissue 
[31]. Furthermore, NFκB is involved in T cell survival and cytokine production and 
promotes the proliferation, differentiation and maturation of B cells. NFκB is also 
important for the signaling and induction of prostaglandins [32, 33] and leukotrienes 
[34, 35]. Finally, NFκB is also active in the resolution of inflammation [31]. In skeletal 
muscle NFκB plays a role in regulating differentiation of cultured myoblasts by 
several mechanisms and in adult muscle NFκB is a part of adaptations such as muscle 
hypertrophy and atrophy [36]. 
In polymyositis and dermatomyositis, NFκB subunits have been extensively 
investigated. Enhanced expression has been documented in endothelial cells of blood 
vessels, atrophic and CD8
+
 invaded non-atrophic muscle fibers and regenerating fibers. 
The expression in fiber nuclei is similar in both myositis patients and healthy 
individuals. In the inflammatory cells infiltrating the muscle tissue, NFκB expression 
has been recorded in both CD4
+
 and CD8
+
 T cells as well as in B cells [37]. 
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4.2 IMMUNE CELLS 
 
4.2.1 T lymphocytes 
Infiltrating T cells are often present in the muscle tissue of polymyositis and 
dermatomyositis patients. The immune cell infiltration follows two different patterns. 
First, the endomysial infiltration of invading CD8
+ 
T cells surrounding non-necrotic, 
MHC I expressing muscle fibers as well as CD4
+
 T cells, DCs and macrophages can be 
seen, preferentially in polymyositis patients. CD8
+
 T cells express granzyme B and 
perforin and is hypothesized to cause muscle fiber injury. Conversely, perivascular 
infiltration comprises CD4
+
 T cells, DCs, macrophages and occasional B cells and is 
predominantly seen in patients with dermatomyositis [38]. T helper 17 (Th17) cells 
have also been detected in muscle tissue in patients with myositis. These cells produce 
IL-17, a pro-inflammatory cytokine capable of inducing MHC class I expression and 
IL-6 production  in cultured myoblasts and could play a role in the pathogenesis of 
myositis [39]. Another subtype of T cells lack the CD28 molecule and CD28
null
 
accumulation in both CD4
+
 and CD8
+
 T cell populations has been reported in myositis 
tissue [40]. These cell populations show treatment resistance and are potentially toxic 
(unpublished data). Tregs are not so extensively present in the muscle tissue and the 
proportion seems to decrease after immunosuppressive treatment in patients with 
polymyositis or dermatomyositis (unpublished data). The interplay between subsets of 
T cells as well as between T cells and other cells in myositis is still not completely 
understood. 
  
4.2.2 Macrophages 
Macrophages play a role in both the innate as well as in the adaptive immune response. 
In the innate response macrophages acts as phagocytes and scavengers, ingesting 
pathogens and removing dead cell material. Antigen presentation and the activation of 
B and T lymphocytes by secreting cytokines are additional roles for macrophages [41]. 
In skeletal muscle post tissue injury and during the following regeneration resident 
macrophages are present in the connective tissue of muscle and participate in the 
regeneration process. The pro-inflammatory response upon injury starts with invasion 
of classically activated M1 macrophages [42] followed by a decline and transition to 
M2 macrophages. M2 macrophages are known as alternatively avtivated and are able to 
release IL-10 and IL-1 receptor antagonist (IL-1ra) [42]. M2 macrophages are present 
during the regenerative phase after tissue damage [43, 44].  The mechanisms 
underlying macrophage subset involvement in tissue repair are not known but 
macrophage depletion in muscle injury models leads to disturbances in muscle 
differentiation, growth and regeneration [45, 46]. Both CD68 and CD163 expressing 
macrophages have been reported to be overexpressed in polymyositis and 
dermatomyositis muscle tissues compared to in healthy individuals [47]. 
  
Muscle tissue infiltrates in myositis are predominantly comprised of T cells and 
macrophages. Whereas the expression of T cells, or at least subgroups of T cells, seem 
persistent to immunosuppressive treatment the numbers of macrophages declines in 
response to drug therapy [48].  
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4.2.3 Others 
DCs, both plasmacytoid dendritic cells (pDCs) which are the major producers of type I 
interferons (IFNs), and the potent antigen presenting myeloid DCs have been reported 
in myositis and are inferred to be involved in the pathogenesis [49]. Other immune cells 
less frequently present in the muscle tissue of polymyositis and dermatomyositis 
patients are B cells [50], natural killer (NK) cells [51, 52], mast cells and neutrophils 
(unpublished data). 
 
 
4.3 CYTOKINES, CHEMOKINES AND ADHESION MOLECULES 
Cytokines and chemokines are soluble molecules important in the immune cell and 
tissue communication. Adhesion molecules are major contributors in immune cell 
transmigration and response. All three types of molecules are generally 
induced/produced by immune cells but muscle fibers could also contribute to the 
production [53, 54]. 
 
4.3.1 Cytokines 
Many cytokines are expressed both in the circulation and in the muscle tissue of 
patients with myositis. The most common of these are the pro-inflammatory interleukin 
(IL)-1α and IL-1β. Whereas IL-1β is solely produced by macrophages and DCs, IL-
is additionally expressed on endothelial cells in capillaries, an expression that seems 
resistant to glucocorticoid treatment [17, 55]. IL-1 promotes proliferation of T and B 
cells as well as augmenting adhesion molecule expression on endothelial cells in 
response to induction by other cytokines such as TNF- IFNs [56-58]. IL-18, or 
IFN-y inducing factor, belongs to the same family as IL-1 and is produced by 
macrophages, DCs, endothelial cells and smooth muscle cells. It is regulated by IL-18 
binding protein (IL-18BP) and enhances T cell maturation, regulates B cell activation 
and antibody production along with the induction of cytokines (TNF-α, chemokines 
and adhesion molecules such as intracellular adhesion molecule (ICAM)-1and vascular 
cell adhesion molecule (VCAM)-1 [59-61]. IL-18 is over-expressed in myositis tissue 
[62, 63] and immunosuppressive treatment leads to diminished IL-18 expression in 
inflammatory cells with a seemingly unaffected expression in tissue capillaries 
(unpublished data). 
TNF-α can activate T cells, B cells and macrophages, induce cytokines and adhesion 
molecule expression. In myositis the expression has been established in both T cells 
and macrophages infiltrating the tissue but also in endothelial cells in dermatomyositis. 
TNF-α can induce the MHC class I expression and might have a direct role in affecting 
muscle weakness [64, 65]. Thus TNF-α is considered to play an important role in the 
pathogenesis of myositis. However, blocking of TNF-α in this patient group has shown 
polymyositis and dermatomyositis [66-68].  
IFNs play a major role in the innate immune response and have been extensively 
studied in myositis. Both type I; IFN-α/β and type II; IFN-γ, exhibit a broad spectrum 
of pro-inflammatory capacity. Data on the presence of IFN-γ in myositis is somewhat 
inconsistent [69-71] whereas the type I IFNs seem to be highly involved in the 
pathogenesis, particularly in dermatomyositis [72]. Reports from gene expression 
analyses present data on overexpression of type I IFN inducible genes and proteins in 
muscle tissue from patients with polymyositis and dermatomyositis [72, 73]. It has also 
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been suggested that a particular type I IFN gene signature in blood highly correlate with 
disease activity in polymyositis and dermatomyositis patients [74, 75]. 
High mobility group box-1 (HMGB-1) is a nuclear protein that can influence 
transcription and also act as an extracellular alarmin upon tissue damage [76]. In 
myositis muscle HMGB-1 has been located to mononuclear cells, endothelial cells and 
the myofibers themselves [77]. HMGB-1 can be released upon proinflammatory 
stimulation from monocytes and macrophages but also from necrotic or damaged cells 
in a passive manner. Released HMGB-1 is able to induce cytokine production, cell 
proliferation, differentiation and chemotaxis [78]. Immunosuppressive treatment in 
myositis patients has been shown to decrease the expression of HMGB-1 along with a 
diminished number of immune cells, but the expression in muscle fibers and in 
endothelial cells of capillaries remained unaffected. This might indicate that HMGB-1 
expression is differently regulated in different cell types and a role for HMGB-1 in 
maintaining MHC class I expression has been implied [77].  
IL-6 is a pleiotropic cytokine produced by T cells, macrophages and endothelial cells 
and is involved in a numerous processes within the immune response [79-82]. In 
myositis, only sparse IL-6 protein expression has been observed in the muscle tissue. 
IL-15, expressed in macrophages and endothelial cells is a cytokine with the ability to 
activate T cells, B cells and NK cells. In addition to the IL-15 receptor alpha (IL-15Rα), 
the biological function of IL-15 can be mediated through the IL-2 receptor, possibly 
causing the functional similarity to IL-2 in T cell activation [83, 84]. Interestingly, IL-
15 has been shown to down-regulate the expression of CD28 on both CD4
+
 [85] and 
CD8
+
 T [86] cells. In the generated CD28
null
 phenotype, IL-15 is able to continue to 
stimulate the growth and augment the cytotoxic properties of these particular T cells 
[87, 88]. High serum levels of IL-15 have been reported in patients with myositis [89] 
and data on IL-15 protein expression in myofibers and myoblasts has previously been 
published [90, 91], indicating that muscle fibers could be a potential source of IL-15. 
 
Several of the pro-inflammatory cytokines have dual effects and besides the 
involvement in the immune response they may also influence skeletal muscle 
metabolism, regeneration and function. This adds complexity in whether biologic 
blockade would be favorable in patients having muscles as the primary organ of 
inflammation.  
In recent years it has been postulated that IL-6 is a so called myokine as it can be 
secreted from muscle fibers upon contraction [54] and it has been suggested that 
exercise induced IL-6 has anti-inflammatory properties and is involved in energy 
metabolism [92].  
TNF-α plays a role in degeneration upon muscle injury and activates satellite cells, 
promoting their proliferation and differentiation [93].  
An additional role for HMGB-1 has been reported in skeletal muscle tissue where it 
may influence muscle fiber regeneration [94-96]. IL-15 is also referred to as a myokine 
secreted from contracting muscle but there are inconsistencies among the reports [97-
99]. Interestingly, IL-15Rα can, without interacting with IL-15, be able to define fast 
skeletal muscle oxidative capacity and fatigue resistance [100].   
 
4.3.2 Chemokines 
Chemokines are cytokines operating the leukocyte migration into tissues by chemotaxis 
and can be divided into two major groups; α-chemokines (C-X-C motifs) and β-
chemokines (C-C motifs). The α-chemokines are INF-γ inducible and CXCL9 and 
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CXCL10 have been localized to both T cells and to various degree in MHC class 1 
expressing myofibers [101]. Myofibers themselves are also a possible source of 
CXCL9 Apart from controlling leukocyte migration; the β-chemokines can also be 
involved in tissue repair and skeletal muscle regeneration, evident by the proliferation 
of myoblast in response to CCL2, CCL3 and CCL4. Muscle fibers themselves might be 
a source of both CCL5 and CCL2 as human myoblasts have shown constitutive 
expression as well as expression upon pro-inflammatory stimulation [53]. A wide 
number of different chemokines have been detected in polymyositis and 
dermatomyositis muscle tissue and may possibly be involved in the pathophysiology of 
these diseases. Some of the chemokines found up-regulated are the α-chemokines 
CXCL9 and CXCL10 [101] and CCL2, CCL3, CCL4 and CCL5 among the β-
chemokines [101, 102]. The expression is often corresponding with the infiltrating cell 
pattern and shows an endomysial or perivascular localization in the tissue [103]. 
However, the interpretation of chemokine expression needs to be cautious as 
discordances between mRNA and protein expression have been reported [103].  
 
4.3.3 Adhesion molecules 
A characteristic feature of muscle tissue in patients with polymyositis and 
dermatomyositis is presence of infiltrating immune cells. Leukocytes can either 
originate from the blood stream or proliferate locally. The homing into the tissue from 
the blood is mediated by the adhesion molecules on the leukocytes as well as on the 
endothelial cells [104]. VCAM-1 and ICAM-1 are both expressed on the vascular 
endothelium and ICAM-1 also on immune cells.  Both ICAM-1 and VCAM-1 have 
been reported to be overexpressed in muscle tissue of patients with myositis, especially 
in an early phase of the disease [105]. The expression in the muscle tissue most likely 
plays a central role in leukocyte infiltration in the disease, an expression that is only 
partly affected by immunosuppressive treatment [106]. The vascular expression, which 
is unresponsive to conventional treatment, could be a potential drug target.    
 
 
4.4 EICOSANOIDS 
Eicosanoids are short-lived, lipid molecules derived from the 20-carbon unit 
polyunsaturated fatty acid arachidonic acid (20:4, ω6). Besides modulating the immune 
response, eicosanoids are also able to alter cardiovascular, pulmonary, reproductive and 
secretory functions in a variety of cells typically via G-coupled receptors. Esterified 
arachidonic acid is stored in cell membrane phospholipids and metabolized along the 
cyclooxygenase pathway to form prostaglandins (PG), the lipoxygenase pathway for 
leukotrienes (LT) production [107] or the cytochrome P450 pathway for 
epoxyeicosatrienoic acid (EET) synthesis [108]. The eicosanoid production progresses 
by the release of arachidonic acid from membrane phospholipids catalyzed by cytosolic 
phospholipase A2 (cPLA2). cPLA2, activated by increases in intracellular Ca
2+
 
concentrations in response to mitogens or cytokines, translocates from the cytosol into 
the nuclear membrane [109]. Here it regulates the release of arachidonic acid and thus 
controls the eicosanoid production.  
 
 
 
 8 
 
Figure 2. Schematic illustration of prostaglandin and leukotriene biosynthesis. Arachidonic acid is 
released from nuclear membrane phospholipids and synthesized down the COX- or 5-LO pathway. 
 
4.4.1 Prostaglandins 
The released arachidonic acid is converted into the unstable intermediate PGH2 by the 
cyclooxygenase (COX) enzymes; COX-1 and COX-2. Under most conditions the 
COX-1 isotype is constitutively expressed in most cells to maintain housekeeping 
functions of the prostaglandins. Conversely, COX-2 is inducible under pro-
inflammatory conditions. However, the opposed functions for both enzymes can occur 
as well [110]. PGH2 is converted into different prostanoids by their respective terminal 
synthase; PGE2 with pro- and anti-inflammatory properties, PGD2 causes vasodilation 
and triggers asthmatic responses, [111] PGF2α controlling contraction/relaxation and 
modulation of inflammation, and the anti-thrombotic PGI2 (prostacyclin) and pro-
thrombotic tromboxane counterbalancing cardiovascular functions [112, 113]. The 
different prostaglandins act in autocrine and paracrine fashions and operate in 
inflammatory responses and vascular stability. Non-steroidal anti-inflammatory drugs 
(NSAIDs), the most common over-the-counter drug inhibit COX enzymes. NSAIDs 
reduce pain, inflammation and fever due to non-selective COX inhibition. As an 
unwanted consequence this may result in gastrointestinal toxicity by the obstruction of 
the PGE2 synthesis produced by COX-1 [114]. To circumvent these adverse effects the 
selective COX-2 inhibitors (coxibs) were developed but they lead to cardiovascular 
complications as a result of a disruption in the balance between PGI2 and TXA2 [115].  
 
4.4.2 PGE2 
The conversion of PGH2 into PGE2 is catalyzed by PGE synthases (PGES). Cytosolic 
PGES-1 (cPGES-1), functionally linked to COX-1 for PGE2 synthesis, is constitutively 
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expressed in a wide variety of cells [110]. Microsomal PGES-1 (mPGES-1) is inducible 
and acts in concert mainly with COX-2 as well as with COX-1 in some conditions 
[116]. The third PGES; mPGES-2 is a constitutively expressed enzyme and 
functionally coupled to both COX-enzymes [117].  PGE2 is the most abundant as well 
as the most pleiotropic prostaglandin and has been extensively studied under numerous 
different conditions. PGE2 is involved in several biologic events, such as 
gastrointestinal protection, renal blood flow, airway homeostasis, hypertension, fertility 
and in immune responses. During inflammation PGE2 controls vascular permeability, 
macrophage and neutrophil infiltration, production of inflammatory mediators but also 
anti-inflammatory functions such as Treg activity and IL-10 induction [118]. PGE2 acts 
through four different receptors, EP1-EP4 that are expressed on a wide variety of cells, 
indicating ubiquitous roles for PGE2. EP3 and EP4 are high affinity receptors for PGE2 
whereas EP1 and EP2 have lower affinity and require higher concentrations of PGE2. 
EP3 is the only PGE2 receptor with several isoforms due to alternative splicing of the 
C-terminal. The signal transduction pathways of the different EP subtypes are mediated 
through regulation of Ca
2+
 concentration, changes in cyclic adenosine monophosphate 
(cAMP)-levels or a phosphatidylinositol (PI) response, however, the EP coupling to 
respective pathway is not exclusive [119-122]. The different sensitivities and 
accessibilities to the receptors add to the complexity of the PGE2 response. In skeletal 
muscle, PGE2 production can be stimulated by IL-1 and TNF [123, 124], both of these 
being markedly expressed in myositis [17, 82]. Involvement of PGE2 has been reported 
in protein turnover and myogenesis, but also in mediating inflammation and muscular 
pain [125-127]. Expression of COX-1 and COX-2 mRNA has been reported in 
polymyositis and dermatomyositis [128], suggesting a role for PGE2 pathway in 
myositis. The downstream mPGES-1 could be a possible drug target in order to reduce 
inflammation without causing side gastric ulcers or cardiovascular side-effects typical 
for traditional NSAIDs or COX-2 inhibitors [129].  
 
4.4.3 Leukotrienes 
As for the prostaglandin production, leukotriene synthesis starts from the cPLA2-
mediated release of arachidonic acid. 5-lipoxygenase (5-LO) catalyzes the two first 
steps in the leukotriene biosynthesis, first the oxygenation of arachidonic acid to 5-
HPETE followed by the dehydration converting 5-HPETE to the unstable intermediate 
leukotriene A4 (LTA4) [130]. 5-LO is expressed on a variety of leukocytes, neutrophils, 
monocytes/macrophages, DCs, and B cells. In a resting state, 5-LO resides in the 
cytosol but upon stimuli it translocates into the nuclear membrane where it actively 
converts arachidonic acid to LTA4 in two reactions [131]. The leukotriene synthesis 
also requires 5-LO activating protein (FLAP), a non-enzymatic scaffolding protein. 
FLAP presents arachidonic acid to 5-LO but can also increase the efficiency of the 
conversion of 5-HPETE into LTA4 thus FLAP and 5-LO are co-localized in activated 
cells. Although their transcriptional regulation differs, 5-LO and FLAP often exhibit 
similar expression [131, 132]. The unstable intermediate LTA4 is transformed into 
either LTB4 or to cysteinyl leukotriene LTC4 which might be further converted into 
LTD4 and LTE4.  FLAP inhibitors acts as broad-spectrum leukotriene modifier drugs 
by blocking the formation of leukotriene B4 as well as the cysteinyl leukotrienes; LTC4, 
LTD4 and LTE4. 
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4.4.4 LTB4 
LTB4 is a potent chemoattractant for T cells and neutrophils and can, in addition, 
promote smooth muscle cell proliferation, leukocyte adhesion and augment vascular 
permeability. LTA4 hydrolase (LTA4H) is a broadly expressed enzyme and converts 
LTA4 into LTB4 [133]. The effects of LTB4 are mediated by the high affinity receptor 
BLT1, primarily expressed on leukocytes, but also on endothelial cells and smooth 
muscle cells. The low affinity BLT2 receptor binds other eicosanoids in addition to 
LTB4 and is ubiquitously expressed [134]. In the context of polymyositis and 
dermatomyositis, LTB4 is interesting as this molecule may be produced in skeletal 
muscle as previously demonstrated in patients with fibromyalgia using microdialysis 
technique [135, 136]. Enhanced expression of 5-LO mRNA has also been demonstrated 
in muscle tissue from patients with polymyositis or dermatomyositis indicating a role of 
the LTB4 pathway role in the pathogenesis of these diseases [137]. In addition to the 
pro-inflammatory effects, LTB4 contributes to muscle regeneration by promoting the 
proliferation and differentiation of satellite cells and differentiation of myoblasts 
through the BLT1 receptor [138]. Thus LTB4 might play an important role in different 
pathogenic processes in inflammatory myositis. However, detailed characterization of 
the LTB4 biosynthetic pathway in muscle tissue from patients with polymyositis and 
dermatomyositis is lacking.  
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5 MUSCLE STRUCTURE 
 
Skeletal muscle, the largest organ in the body, is highly adaptable, and responds well to 
physiological as well as pathological challenges. To understand the skeletal muscle 
weakness and reduced muscle endurance in patients with polymyositis and 
dermatomyositis not only the effects of the immune responses, but also mechanisms in 
normal muscle physiology need to be clairified.  
 
 
5.1 MUSCLE FIBER TYPES 
Muscle fibers are generally divided into fast and slow twitch fibers depending on their 
contractility. Whereas the slow twitch, oxidative type I fibers mainly are used for 
aerobic endurance work the fast twitch, glycolytic type II fibers are predominately 
made for more explosive, shorter pulses of high-intensity muscle work. Type II fibers 
can be further divided into subtypes; type IIA contain a mix of oxidative and glycolytic 
features, type IIB is highly glycolytic and type IIC is a developmental, transient type 
that could differentiate to exhibit either oxidative or glycolytic characteristics [139, 
140]. Different muscle groups are constituted of somewhat different proportions of the 
type I and type II fibers respectively, depending on the distinctive demand on that 
specific muscle. One of the quadriceps in thigh muscle; m.vastus lateralis is generally 
composed by an approximately equal number of slow and fast twitch fibers [141]. 
 
 
5.2 MUSCLE CONTRACTION 
A muscle contraction is initiated by the nervous system communicating with skeletal 
muscle fibers by the release of the neurotransmitter acetylcholine at the neuromuscular 
junction, thereby producing an action potential that spreads along the whole muscle 
fiber. Released Ca
2+
 ions from the sarcoplasmic reticulum (SR) bind to troponin, which 
induces a conformational modulation of tropomyosin uncovering the  myosin binding 
sites. This allows an interaction between myosin and actin and by utilizing stored ATP, 
a cross-bridge cycle is created and the muscle contracts. Muscle contraction therefore 
consumes a vast amount of ATP and resting muscle fibers only contain enough ATP 
and creatine phosphate (CP) reserves to sustain a contraction until new ATP has been 
generated. Energy release starts with the breakdown of dietary macronutrients and 
stored glycogen during glycolysis, where pyruvate is generated from glucose. In the 
absence of oxygen, glycolysis itself can generate a small amount of ATP used for 
anaerobic muscle contraction but the majority of ATP released comes from the citric 
acid cycle and electron transport chain in the mitochondria [142, 143].  
When the muscle no longer can continue to perform contractions, it is said to be 
fatigued. Causes underlying muscle fatigue could for example be pulmonary, 
circulatory or microvascular insufficiency, sarcoplasmic dysfunction or mitochondrial 
enzyme insufficiency that may affect the energy process in the mitochondria [142, 144, 
145]. 
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5.3 MUSCLE FIBER PLASTICITY 
Muscle fibers exhibit plasticity, in the sense that they are highly adaptive and can alter 
upon different physiological or pathological demands. Steroid myopathy, ageing, 
disuse, hypoxia and physical exercise are some examples of conditions where fast-to-
slow or slow-to-fast transitions have been described [140]. Adaptations could be seen 
as an increased proportion of type IIC fibers, the intermediate fiber type between type I 
and type IIA [146]. Suggested mechanisms for the switch from slow-to-predominantly-
fast twitch muscle fibers are through transcription factor FOXO1 induction and 
suppression of muscle oxidative capacity by inhibiting calcineuring pathway [147]. 
Another transcription factor that has been implied to be involved is chREBP, regulated 
by glucose [148]. At present there is only one report of high levels of glucose 
promoting a slow-to-fast shift in muscle fibers via chREPB. In patients with chronic 
myositis a characteristic feature of muscle tissue is low content of slow contractile, 
oxidative fibers in m.vastus lateralis, suspected to play a role in the impaired muscle 
endurance in polymyositis and dermatomyositis [149].  
 
The fiber cross-sectional area (CSA) determines muscle force and correlates with 
muscle strength in healthy individuals. Atrophied muscle fibers, i.e. a reduced CSA, 
can be a consequence of several pathological conditions and the type II fibers in 
particular, seem to be sensitive [140]. In myositis fiber atrophy has been reported in 
text books and articles and is seen as either perifascicular atrophy or scattered 
throughout the muscle tissue [3]. In more recent years, these atrophic fibers have been 
considered being of a more regenerative type that could explain differences in muscle 
fiber size. Through the literature there has not been a standardized method to 
investigate cross-sectional area. Thus results from the earlier studies are difficult to 
compare with each other [150, 151]. In general, the cross sectional area of the different 
muscle fiber types in m.vastus lateralis is larger for men than for women. Type II fibers 
in women tend to be smaller than the type I fibers while the opposite relationship is 
seen in men [141]. 
 
 
5.4 MUSCLE REGENERATION 
Upon skeletal muscle injury, caused by trauma or micro tearing of muscle fibers caused 
by strenuous exercise the onset of the following inflammatory response follows a fairly 
consistent pattern [152, 153]. If the muscle repair mechanisms are inadequate, the 
consequence might be reduced muscle function and muscle wasting [152]. Signs of 
fiber degeneration and regeneration are classical histopathological features of 
myositis, but to what extent the inflammatory response in myositis is a feature that 
promotes muscle injury or muscle growth and repair is still not fully understood. 
An initial step in muscle degeneration with fiber necrosis is the disruption of the 
sarcolemma followed by increased serum levels of proteins such as CK [154]. 
Initially, the injured muscle activates an inflammatory response driven by Th1 
cytokines, such as IFNγ and TNF-α. Phagocytes such as neutrophils and M1 
macrophages respond early in the process in order to remove cell debris. After the 
pro-inflammatory phase, quiescent muscle satellite cells are activated by different 
growth factors and starts proliferating and migrate to the site of injury. The muscle 
progenitor cells develop into myoblasts and promoted by IL-4, IL-10 and IL-13, the 
macrophage profile switches to M2 macrophages, present in wound-healing tissue 
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[45]. Following the proliferation stage the myoblasts become terminally differentiated 
myotubes and fuse with each-other to replace the damaged fibers [154]. At present, it 
is not possible to distinguish the features of the chronic inflammatory response in 
autoimmune myositis that causes damage from those that promote muscle 
regeneration and repair. 
 
 
 
 
Figure 3. A schematic diagram illustrating the positive effects on muscle fiber regeneration and 
remodelling of molecules that might have a dual role inmuscle tissue both promoting inflammation and 
affecting skeletal muscle fiber regeneration and remodelling in myositis patients. The key molecules 
can influence each other (red arrows) as well as the different phases of skeletal muscle regeneration; 
the focus in this diagram is on the less frequently described positive effects (blue arrows) rather than 
the established negative effects. The broken blue arrow indicates inhibiting effects on muscle fiber 
differentiation. Upon skeletal muscle fiber damage, anti-inflammatory ⁄ immune response precedes 
myogenesis. The local immune response in muscle tissue has a direct effect on satellite cell activation, 
proliferation, differentiation or fusion. This local immune response might be disturbed (e.g. by 
immunosuppressive treatment), thus potentially influencing the functional restoration of fibers injured 
in various ways. Therefore, suppressing the immunesystem or blocking single cytokines or receptors 
might disturb skeletal muscle regeneration. Picture originally published in J Intern Med 2011. Re-
printed with permission from John Wiley and Sons Inc.  
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6 TREATMENT 
 
6.1 IMMUNOSUPPRESSIVE TREATMENT 
The general concept of immunosuppressive treatment is to reduce the activity of the 
immune response. The suppression could involve specific target molecules or in a 
broader range, affecting several inflammatory pathways. Under optimal conditions the 
treatment only affects the intended mechanism but this is rarely the case and 
immunosuppressive drugs often pose a risk of side-effects. Below, the most common 
types of immunosuppressive treatments in polymyositis and dermatomyositis are 
presented. 
 
6.2 GLUCOCORTICOIDS  
Glucocorticoids are the first line of treatment in inflammatory and autoimmune 
conditions. These drugs have been extensively used since they were discovered in the 
late 1940s and the effectiveness is well proven although the responses vary largely 
between individuals. The physiological control of glucocorticoids involves regulation 
of carbohydrate, protein and fatty acid metabolism. The side-effects of glucocorticoid 
treatment are also well established and include Cushing syndrome, osteoporosis, 
diabetes mellitus and steroid myopathy, necessitating a demand for a tightly balanced 
administration in order to yield the most potent effect while keeping the adverse 
properties of the drug to an absolute minimum. To improve their efficacy and safety 
synthetic glucocorticoids should exhibit more glucocorticoid influence and less 
mineralocorticoid activity. More tailored methods of administration targeting the site of 
inflammation are also desirable.  
 
The effects of glucocorticoids are dose-dependent and are determined by the rate of 
absorption, metabolism as well as the affinity for the glucocorticoid receptor. In 
myositis, the recommended initial dose is 0.75mg/kg bodyweight, which generally is 
around 60mg/day. This high dose is administrated during 2-4 weeks and tapered with 
approximately 2.5-5mg/month.  
 
 
6.3 MECHANISMS OF GLUCOCORTICOID ACTION 
As they are lipophilic in their structure, glucocorticoids can passively diffuse across 
plasma membranes and interact with cytosolic glucocorticoid receptors (GRs). The GR 
is a heteromeric complex that belongs to the steroid hormone receptor family and acts 
as a ligand-activated transcription factor. Ligand-free GR heteromers form complexes 
together with chaperones (e.g. heat shock proteins (Hsp’s)) and co-chaperones (Hsp-
binding or organizing proteins) [155]. The components in this receptor complex could 
act as modulators of affinity, nuclear translocation and also link steroid hormones to 
other signalling pathways. The glucocorticoid-GR association causes receptor 
activation and dissociation from its chaperones and modulators followed by a 
translocation into the cell nucleus, taking place within 10-30 min after glucocorticoid 
exposure.  
In the nucleus the GR interacts with binding sites on the DNA called glucocorticoid-
responsive elements (GRE) that are located in the promoter region of target genes 
[156]. The interaction could either be direct with GRE, or by protein-protein interaction 
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upon association with transcription factors on the DNA. Depending on what target gene 
the glucocorticoid-GR complex has bound the effects of either transactivation or 
transrepression can start, up to 120 minutes after entering the nucleus. 
 
6.3.1 Transactivation 
The GR complex enters the nucleus, binds to GRE sequences and activates the 
transcription of its target genes. Among the target genes are anti-inflammatory 
mediators such as IL-10, annexin 1 and inhibitors of NFκB. Additionally, transcription 
is initiated for regulator proteins important for metabolism and thus transactivation is 
considered to be the pathway that induces most side-effects of glucocorticoid treatment 
[157]. 
 
6.3.2 Transrepression  
Transrepression is the main mechanism through which GR exerts its anti-inflammatory 
activities. Repression of a target gene could either be executed through binding to a 
GRE overlapping another transcription binding site thus blocking this gene, or by 
interacting with a transcription factor in an adjacent binding site and could in this way 
alternate the neighbouring gene transcription [157].  
 
6.3.3 Non-genomic effects 
Non-genomic effects are the actions upon glucocorticoids binding to GR but not 
depending on the subsequent binding to the glucocorticoid responsive elements 
(GREs). GR could regulate gene activation without binding directly to GRE segments 
on the DNA. Instead GR may physically interact with other transcription factors (e.g. 
AP-1 or NFκB) and thereby alter the gene expression [29, 158]. Through 
transrepression, GR can inhibit the genes that are under control of transcription factor 
NFκB; IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-18, COX-2, IFNs, TNF, CCL2 and 
VCAM [155, 157].  
In addition, if high doses of glucocorticoids are given intravenously or intra-articularly, 
rapid responses that cannot origin from transcriptional alterations occur. These effects 
could be mediated by the proteins dissociating from the activated GR-complex [159]. 
Upon the detachment from the GR-complex, Src tyrosine kinase is able to mediate 
tyrosine phosphorylation of the epidermal growth factor receptor (EGFR), resulting in 
the inhibition of arachidonic acid release and eicosanoid synthesis [159]. Specific 
interactions with membrane-bound GRs, i.e. found on monocytes in RA [160], or non-
specific interactions with plasma or mitochondrial membranes, may interfere with the 
membrane potentials, disrupting Ca
2+
 or Na
+
 levels and thereby prevent signalling or 
ATP synthesis [158, 161]. 
 
6.3.4 Induction of apoptosis in inflammatory cells 
In order for GR to induce apoptosis in a cell, the cell seems to require a certain level of 
endogenous GR protein and examples of immune cells susceptible to GR-induced 
programmed cell death are T cells and monocytes. Glucocorticoids are believed to 
induce apoptosis through both transrepression and transactivation mechanisms upon 
transcription factors and cytokines required for survival [155]. 
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Figure 4. Schematic illustration of the immune modulation by glucocorticoids. Glucocorticoids bind to 
GR and translocates into the nucleus where it can modulate inflammation via both genomic and non-
genomic mechanisms. GR=glucocorticoid receptor 
 
 
6.4 SIDE-EFFECTS OF GLUCOCORTICOIDS 
Diabetes or hyperglycemia is a very common side-effect in glucocorticoid treated 
patients. The primary role of glucocorticoids is to maintain blood glucose levels and the 
anti-insulin effect is accomplished by blocking glucose uptake in tissues. In addition, 
glucocorticoids up-regulate gluconeogenesis by increasing protein breakdown in order 
to release amino acids for glucose production . 
Glucocorticoids induce bone loss and glucocorticoid-induced osteoporosis is often 
associated with fractures. The mechanism underlying the low bone turnover is the 
glucocorticoid stimulation of osteoclast differentiation and function along with 
inhibition of the same features in the osteoblasts [162].  
Hypertension is a common side-effect in steroid treated patients. Approximately 20% 
of patients treated with exogenous glucocorticoids have been reported to have 
hypertension and research of the mechanisms involved is at present focused on 
oxidative stress and nitric acid interaction with eicosanoid synthesis [163].   
The glucocorticoid effect on skeletal muscle proteins acts through inhibition of protein 
synthesis and induction of protein breakdown, mainly via the ubiquitin-proteasome 
pathway. Glucocorticoids can also induce the expression of myostatin, an important 
negative regulator of muscle growth [164]. 
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6.5 STEROID MYOPATHY 
Steroid myopathy is a non-inflammatory, toxic myopathy in response to high doses of 
glucocorticoids. The clinical manifestations remind a great deal of what patients with 
polymyositis and dermatomyositis experience from their disease i.e. proximal muscle 
weakness affecting daily life activities such as walking up stairs and rising from chairs. 
The mechanism underlying steroid myopathy is not known and there is no clear 
relationship between glucocorticoid dose or period of administration and the weakness 
[165]. In addition to the weakness and fatigue the muscle fibers display a shift from 
fast-to-slow twitch fiber predominance and selective type II atrophy [164]. The 
histopathological features tend to vary inter-individually due to disease and treatment 
duration, glucocorticoid dose, nutritional status and physical activity. 
Electromyography (EMG) looks normal within most patients and serum creatine kinase 
(s-CK) tends to stay within normal range [165]. 
 
 
6.6 DISEASE MODIFYING ANTI-RHEUMATIC DRUGS 
Second-line disease-modifying anti-rheumatic drugs (DMARDs) can be used in order 
for patients to taper off the glucocorticoids more rapidly. There are several 
immunosuppressive agents used and they are selected based on clinical experience and 
some case series. Metotrexate (MTX) and azathioprine (AZA)are the most commonly 
used immunosuppressant added in myositis drug therapy and are well tolerated. 
Cyclophosphamide and cyclosporine A (CsA) are often used if the patient exhibit 
pulmonary involvement. Mycophenolate mofetil (MMF) is an immunosuppressive 
alternative to azathioprine, suppressing T cells and B cells [166, 167]. 
Intravenous immunoglobulin (IVIG) is composed by IgG antibodies from around 
1000 blood donors and is able to modulate the immune response in the recipient. 
IVIG is sometimes the choice in refractory myositis [168].  
 
 
6.7 BIOLOGIC AGENTS 
Biological agents have been available for over a decade and the first agents available 
were TNF-blockers. The mechanisms behind the drug action are involved in the 
prevention of TNF- receptor binding, thereby reducing inflammation. The efficacy of 
TNF-blockade in myositis has only been evaluated in case series with diverse outcomes  
and in a uncontrolled study including 13 patients with refractory myositis, where 16 
weeks of TNF-blockade resulted in disease flares in some patients [66]. 
Rituximab, an anti-CD20 antibody causes B cell depletion and has been shown efficacy 
in case series in polymyositis and dermatomyositis [169-171]. 
IL-1 and IL-1R are both up-regulated in muscle tissue of myositis patients and the 
expression persists after conventional immunosuppressive treatment. Based on those 
data, therapy with IL-1 receptor could be a treatment prospect. To this date, only one 
case report on myositis has been published, and one open-label study undertaken at 
Karolinska University Hospital has shown some positive results [172]. 
 
 
6.8 EXERCISE 
Until quite recently patients with polymyositis and dermatomyositis were advised 
against physical activity since it was believed to worsen the inflammation. However, 
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less obedient patients cleared the way for studies showing that not only was physical 
exercise safe to perform, but rather that it improved strength, oxygen capacity and 
quality of life [173-175] in patients with IIM. Thus exercise has evolved into an 
important part of treatment in myositis patients and the optimal training regimen now 
needs to be established. A 12-week muscle endurance program has been shown to 
restore the skewed fiber type distribution (lower proportion of oxidative fibers) in 
patients with chronic myositis [149]. Intensive resistance training seem to reduce 
expression of genes regulating inflammation and fibrosis as well as decrease the 
clinical disease activity in myositis patients [176]. In addition, creatine supplementation 
has been reported to enhance the improvements from exercise in patients with 
polymyositis and dermatomyositis, with no relevant adverse effects [177]. However, it 
is not recommended as part of standard care for patients with polymyositis or 
dermatomyositis with immunosuppressive treatment. Today, exercise research in adult 
myositis is focused on understanding mechanisms for muscle impairment and improved 
muscle function in relation to exercise. 
 
Both chronic and acute exercise can modulate the immune response although the 
mechanisms are less clear. Studies primarily focus on circulating immune cells and 
cytokines that may not necessarily reflect the status in the tissue. Contracting muscle 
fibers have the ability to produce and release IL-6 [54, 92] and the myokine release (IL-
6, IL-8 and MCP-1) from skeletal muscle during the inflammatory response after heavy 
resistance exercise seem to be under the transcriptional control of NFkB [178]. More 
studies on exercise in patients with polymyositis and dermatomyositis are needed. 
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7 AIMS OF THIS THESIS 
 
The overall aim of my doctoral studies has been to do a broad-ranging investigation of 
changes in muscle molecules and phenotypes before and after immunosuppressive 
treatment in patients with polymyositis and dermatomyositis. By performing detailed 
studies of muscle tissue from the patients, I have investigated pathways and 
circumstances that might be involved in the pathogenesis of myositis and that could 
provide more information on possible characters involved in the muscle weakness and 
low muscle endurance in polymyositis and dermatomyositis. 
 
The specific aims were; 
 
 To determine the role of muscle tissue IL-15 and IL-15Rα expression in 
patients with polymyositis or dermatomyositis, the relation to clinical 
symptoms and the influence of immunosuppressive treatment. 
 
 To examine the influence of PGE2 pathway as well as the consequence of 
immunosuppressive treatment on the PGE2 biosynthetic enzymes in patients 
with polymyositis or dermatomyositis. 
 
 To investigate the significance of LTB4 pathway in polymyositis and 
dermatomyositis and to study the impact of immunosuppressive treatment on 
the proteins involved.  
 
 To confirm the presence of in vivo bioactive LTB4 in patients with 
polymyositis and dermatomyositis in the relation to functional performance. 
 
 To investigate if the low proportion oxidative muscle fibers seen in chronic 
polymyositis/dermatomyositis patients might have a role in the disease 
pathogenesis and low muscle endurance. 
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8 PATIENTS & METHODS 
 
In this thesis, the core investigations have been performed on muscle tissue from 
patients with polymyositis and dermatomyositis at the time point of diagnosis and at 
follow-up after approximately six months of treatment. The time frame of six months 
was when practiced difficult to maintain and the second measure point could readily be 
delayed by several months. Newly diagnosed patients have also been compared to 
chronic, treatment responsive and non-responsive patients as well as different cohorts 
of healthy individuals.  
 
I have personally performed or participated in every step in every method except 
culturing and staining myotubes. For this I have had the pleasure of benefit from the 
expertise from highly appreciated co-workers. 
 
 
8.1 PATIENTS AND HEALTHY CONTROLS 
Muscle biopsies from patients with polymyositis and dermatomyositis and healthy 
individuals formed the basis of my studies. For the different studies somewhat different 
patient groups were included depending on the research questions that were to be 
addressed.  
Most patients included were recruited from the rheumatology unit at Karolinska 
University Hopital except for one patient (papers I, II, III and IV) who belonged to 
Malmö University Hospital. Additional patients were also included from Sahlgrenska 
hospital in Gothenburg and Akademiska hospital, Uppsala based on a multi-centre 
collaboration (paper III) 
 
Patients who were followed longitudinally in the rheumatology clinic with structured 
clinical follow up and a repeated muscle biopsy performed after a median of 8 months 
of disease treated with conventional immunosuppressive therapy is the major cohort of 
my studies. Mucle biopsies from these patients are included in all studies (paper I, II, 
III and IV). The patients were treated according to the choice of the treating physician. 
 
In addition:  
In paper II we included nine patients, with new onset polymyositis or dermatomyositis 
without follow-up biopsies available and three treatment resistant patients.   
In paper III we included microdialysis samples from patients with established 
polymyositis or dermatomyositis. The microdialysis was performed before an exercise 
intervention study. 
In paper IV we also included muscle biopsies patients with established disease and 
treatment-refractory patients (non-responders). 
 
Six muscle biopsies from healthy volunteers were made available as controls through 
collaboration with the Neurology clinic, Karolinska Hospital (paper I, II, III and IV). 
In paper IV, five additional healthy volunteers from the same neurology clinic was 
included. 
For the exercise intervention study (paper III) healthy controls were selected on age 
and level of physical activity among relatives of the included patients and nursing staff. 
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8.2 MUSCLE BIOPSY 
The percutaneous biopsy needle was introduced by Bergstrom in 1962 to be used for 
diagnostic purposes as well as in research. At the rheumatology unit at Karolinska 
University Hospital the Weil-Blakesley conchotome is the preferred tool for collecting 
muscle tissue from patients with myositis. Muscle biopsy is an important diagnostic 
tool used for histopathology, but can also be used in mRNA and protein analysis. For 
research purposes where repeated biopsies are taken, the percutaneous conchotome 
biopsy or semi-open biopsy [179, 180] can be used. This technique gives a good 
sample size, as opposed to the more widely used needle biopsy and minor discomfort 
for the patient. It is specific for detecting inflammation but since their patchy nature, 
infiltrates may be missed. 
 
 
8.3 FIBER TYPING & CROSS-SECTIONAL AREA 
To discriminate between the different the myosin isotypes in m.vastus lateralis the 
diverse sensitivity of their ATPase activity to alkali or acid preincubations is used and 
the human skeletal muscle fibers can be classified into slow-twitch, fast-twitch and 
intermediate variants of fibers. This histochemical method is carried out at different 
pHs of 4.3, 4.6 and 10.3. The resulting images needs to be compared to each-other in 
order to discriminate between the fiber types. Oxidative fiber type I, and the more 
glycolytic type IIa, IIb or the intermediate/developmental type IIc appear in black, 
white and shades of grey depending on the preincubation pH of the tissue. ATPase 
staining is widely used and has been so for over 40 years. Even though it is a solid 
method there are disadvantages such as the need for multiple, consecutive sections and 
the fact that the staining fades over time. Alternatives or as a complement, 
immunohistochemical double-staining with antibodies against different isoforms of 
myosin heavy chain (MyHC) could be used and would provide the same information in 
one tissue section and be more preserved against fading.  
 
In order to analyze the cross-sectional area (CSA) of the muscle fibers, nicotinamide 
adenine dinucleotide (NADH) staining was used and approximately 50 fibers of type I 
and type II, respectively was measured. We used computerized software and a work 
tablet featuring a wireless, pressure sensitive pen for optimal precision as the 
circumference was measured. NADH staining is appropriate for measuring muscle fiber 
CSA as it does not provide any shrinkage to the tissue. Type I fibers appears as dark 
blue and type II as light blue but NADH staining is preferably cross-referenced with 
ATPase staining to determine the fiber type measured. 
 
 
8.4 IMMUNOHISTOCHEMISTRY & IMMUNOFLUORESCENCE 
In order to detect the presence and as well as to study any alterations on cellular and 
protein levels in muscle tissue, immunohistochemistry (IHC) was the predominantly 
method performed. To determine the cellular localization of some markers 
immunofluorescence was used. Cross-sectioned muscle tissue gives a very 
comprehensive picture of the local muscle milieu in the patients with myositis. 
Antibody-stained tissue sections not only render information about the protein 
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expression but also general information regarding muscle morphology, infiltration of 
inflammatory cells, muscle degeneration or regeneration. Critical for these types of 
analyses is the tissue preparation. The first important step is how to freeze the muscle 
specimen in order to avoid artefacts. In our department the biopsies are placed in 
isopentane pre-chilled with liquid N2 within a time frame of approximately 3-15 
minutes after the biopsy has been collected. This has been shown to reduce the freezing 
artefacts that could develop by placing the muscle tissue directly into liquid N2. Placing 
some ice crystals in the tube before freezing the samples may also improve tissue 
histology despite freeze storage. Sectioning muscle tissue properly in a cryostat 
requires patience and experience and in our lab the usual protocol is to either freeze the 
sections for future acetone fixation directly before performing cell surface staining or to 
fix the samples in formaldehyde for intracellular staining. 
 
Evaluation and analysis of IHC staining can be made using a conventional microscope 
either qualitatively describing and/or semi-quantitatively scoring the expression pattern. 
To reduce the subjectivity of the analysis computerized image analysis administers a 
more automated routine but still the settings of the computer programs needs to be 
generated by the evaluator. With the equipment and software used in this thesis it was 
not achievable to discriminate between the positive staining intensities in the sample. 
 
 
8.5 PRIMARY MYOTUBE CULTURE 
As it is challenging to perform experiments on skeletal muscle in vivo, culturing 
myoblasts from skeletal muscle satellite cells becomes a useful technique. The muscle 
cell culture is flexible in the way that one can stop and maintain at any stage according 
to the investigational agenda. From digested muscle biopsies, muscle/satellite?? cells 
are extracted and cultured into myoblasts and further differentiated into myotubes.  
Myoblasts are muscle precursor cells with reasonably similar metabolic characteristics 
to adult skeletal muscle. However, myoblasts are mononuclear cells that upon fusion 
become the multinucleated myotubes. Despite its convenience, an in vitro culture 
cannot represent the in vivo situation and therefore, the interpretation of the results must 
be done with cautiousness.   
 
 
8.6 MICRODIALYSIS 
Microdialysis is a way to collect molecules via a semi-permeable membrane from the 
interstitial space. The technique has been around for somewhat 30 years and has 
developed into a tool for monitoring small molecules in the biochemistry of peripheral 
tissues. Microdialysis is minimally invasive and allows chemical communication 
within an intact organ. The technique accumulates, with the exception of glucose and 
lactate, volumes ranging from micromolar to nanomolar that might put demands on the 
analytical methods used. Despite any challenge to analyse small volumes of dialysate, 
microdialysis is a method with good prospects for the future providing human in vivo 
study conditions where inflammation and muscle metabolism can be investigated.  
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8.7 ENZYME IMMUNOASSAY 
For the analysis of microdialysis eluate we used a LTB4 enzyme immunoassay (EIA) 
kit. The method is a competitive, heterogenous binding assay where the antigen in the 
microdialysis sample competes with labeled, LTB4 Tracer to bind with antibodies. The 
amount of bound Tracer measured is inversely related to the concentration LTB4. EIA 
is a common method to analyze lipid mediators in liquids and tissue extracts. The 
advantages are the detection limits, usually ranging within nanogram to pikogram and 
also the analysis of compounds can be done with little or no preparation and therefore 
circumvents the rapid degradation of LTB4.  
 
 
8.8 MICROARRAY 
Gene expression profiling can provide an overview of the consequences in the 
expression of genes involved in inflammation and muscle tissue alterations in the same 
tissue section. This is a method that quickly delivers a large amount of data that can be 
further used to search for prognostic markers or create other hypothesis-driven studies. 
For the experiments performed and discussed in this thesis, Affymetrix array platform 
was used. The GeneChip® oligo array has been widely used but has, along with every 
platform manufacturer both advantages and disadvantages. The major obstacle when 
using microarray is rather in the variability that could origin from each stage in the 
experiment reaching from the study design to the analysis and interpretation of the 
large amount of data generated. Analysis of paired samples e.g. before and after an 
intervention, reduces the problem with inter-individual variations. The data generated 
reflects the mRNA and should preferably be combined with protein analysis to be 
biologically relevant. This method was not used in any of the papers but the results will 
be discussed in relation to the results generated in papers I-IV. 
 
 
8.9 CLINICAL OUTCOME MEASURES 
 
8.9.1 Cumulative dose of prednisolone  
The starting dose of glucocorticoids administrated to patients with early myositis is 
approximately 40-60mg/day depending on the patient’s body weight. The immediate 
clinical response may vary a great deal from patient to patient but normally the dose 
can be tapered within 4 weeks. If the patient does not experience any flares, the 
tapering continues until the medication can be stopped or a sufficient low maintenance 
dose has been attained. In order to detect any differences in clinical or molecular 
changes due to the total amount or average prednisone the patient has been exposed to 
the cumulative dose of prednisone up to the time of investigation was estimated. Every 
patient file chart was reviewed and every change of dosage and tapering plan recorded 
in order to get an as precise estimation as possible. In those cases where the patient 
belonged to a collaborating hospital, the responsible physician made the clinical 
information available thus all the estimations were made by the same person to limit 
errors. 
 
8.9.2 Serum creatin kinase / creatine phosphokinase 
One diagnostic criterium of myositis according to Bohan and Peter [4, 5] is elevation of 
muscle enzyme activities in serum and measuring the levels of s-CK in myositis 
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patients is routine practice at. S-CK is traditionally considered a very useful enzyme in 
the diagnostic workup of myositis patients as it is relatively specific for muscle and 
highly sensitive to muscle injury but it is not specific for myositis. Increased s-CK is a 
result of damaged muscle fibers and no statistical correlation between s-CK and 
myositis disease activity or muscle strength has been proven [181]. Normal reference 
values for s-CK varies since resting levels depend on the amount of muscle mass, thus 
men have higher s-CK levels compared to women. Dermatomyositis patients also tend 
to have a higher incidence of normal s-CK as some patients have a presence of skin 
rash, making it easier to set the diagnosis at an early time point [181, 182]. 
As an outcome measure, s-CK is somewhat blunt. Magnetic resonance spectroscopy 
may be a more sensitive measurement of disease activity but it is expensive and not 
available to do in routine practice. 
  
8.9.3 Functional Index 
Functional index (FI) of myositis was first developed in the 1990s and measured a total 
of 14 sets of different exercises involving grip strength, elbow ﬂexion, shoulder ﬂexion 
and abduction, hip ﬂexion and abduction, step test, heel, toe and head lifts, and finally 
sit-ups. The index demonstrates disability in patients with myositis and has a maximal 
capacity score of 64 per body side [183]. The total score of the method creates a ceiling 
effect and in order to show improvement (20%) patients need to have a quite low start 
level which makes it a less optimal outcome measure. The original FI was revised in 
2006 and did successfully remove the ceiling and floor effects [184], but still the 
measure contains an interval that could limit the practice.  
 
8.9.4 Manual muscle test 
Manual muscle test (MMT) is a commonly used method for documenting muscle 
impairment. The test involves proximal, distal and axial muscles. It was evaluated by 
the International Myositis Assessment and Clinical Studies group (IMACS) and is a 
tool to assess muscular outcome in patients with myositis in clinical practice and for 
longitudinal follow-up in therapeutic trials. In MMT8 used in this thesis, eight muscle 
groups are tested, including 1 axial, 5 proximal (two upper and three lower extremities) 
and two distal muscles (one upper and one lower extremity) with a maximum score of 
80 [185]. As for FI, the maximum score of MMT gives a ceiling effect where actual 
improvements could get lost in the follow-up if the patient is not severely impaired 
from start. Still, the information obtained is valuable for correlating the molecular data 
with a clinical measurement.  
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9 RESULTS & DISCUSSION 
 
Pro-inflammatory mediators are up-regulated in muscle tissues of polymyositis 
and dermatomyositis  
Many markers of inflammation have previously been studied in myositis muscle tissue; 
MHC class I molecules expression by the muscle fibers, different subsets of T cells, 
macrophages, DCs along with cytokines and chemokine levels. In the present study we 
aimed to determine the involvement of the cytokine IL-15 and IL-15Rα in muscle 
tissues of polymyositis and dermatomyositis patients as IL-15 is a T cell activating 
cytokine and T cells are believed to have a role in the pathogenesis of myositis. We 
were able to confirm an over-expression of IL-15, localized the IL-15 expression to 
CD163
+ 
resident macrophages and for the first time demonstrated expression of IL-
15Rα in myositis muscle (paper I). IL-15 expression in muscle tissue from 
polymyositis and dermatomyositis has previously been reported in a study of very few 
patients [90, 186]. Here we could establish that myoblasts but not differentiated 
myotubes expressed IL-15, which is in contrast to the previously published study. The 
expression of IL-15 in macrophages was co-localized with CD3
+
 T cells in the muscle 
tissue inflammation possibly indicating a role for IL-15 in T cell activation.  
 
Prior publications have reported that IL-15 could promote the loss of CD28 on T cell 
membranes and enhance the progression and cytotoxicity in the generated CD28
null
 
subset [85, 86]. The involvement of IL-15 in the development of CD28
null
 T cells is 
interesting since our group previously reported a high frequency of CD28
null
 T cells in 
peripheral blood and in muscle tissue of patients with polymyositis or dermatomyositis 
[40]. T cell expression does not seem to respond to immunosuppressive treatment 
(papers I, II & III) and the proportion of CD28
null
 T cells is increased after treatment 
(unpublished data).  Using a regression analysis we could conclude a statistically 
significant correlation between IL-15 and CD28
null
 expression in the muscle tissue of 
this cohort of patients (unpublished data). Thus one could speculate that the role of IL-
15 in polymyositis and dermatomyositis is to promote the loss of the CD28 molecule 
and to contribute to the persistence of the local inflammation.   
 
IL-15Rα was detected in mononuclear cells within the same infiltrates as the IL-15 
expressing cells and a positive correlation between IL-15 and the receptor was shown. 
IL-15Rα was also frequently seen in both endothelial cells of larger vessels and in 
capillaries similarly to the healthy individuals. 
 
Additional roles for IL-15 and IL-15Rα seem to be to influence muscle phenotype in 
different ways. Loss of IL- IL-15Rα gives a more fatigue resistant muscle in mice due 
to an adaptive increase of oxidative fibers and mitochondrial content [100]. The IL-15 
and IL-15Rα expression in capillaries and vessels was similar in both patients and 
healthy individuals and immunosuppressive treatment did not have any effect on their 
expression. This may indicate a role for IL-15 and its receptor in muscle metabolism. 
To investigate this, biopsies from the same muscle in all included patients need to be 
compared.  
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The involvement of eicosanoids in myositis has not been much investigated. PGE2 and 
LTB4 are potent mediators of inflammation, produced in skeletal muscle and the 
different arachidonic acid pathways show prospects as probable drug targets. Thus the 
pathways of PGE2 (paper II) and LTB4 (paper III) were investigated in patients with 
polymyositis and dermatomyositis.  
 
In the PGE2 pathway we could determine an overexpression of COX-1, COX-2 and 
mPGES-1 in patients compared to healthy individuals and mPGES-1 was 
predominantly found in infiltrating macrophages. Overexpression of IL-1 and TNF in 
the muscle tissue of patients with myositis could play a role in the induction of 
mPGES-1 in macrophages [123, 124, 187]  thus contributing to PGE2 production in 
polymyositis and dermatomyositis patients. 
 
In the LTB4 pathway, we could record an up-regulation in cells expressing 5-LO and  
the BLT1 expression in capillaries in comparison to healthy individuals. In patients, 
BLT1 expression in cells or larger vessels did not differ from healthy controls. The total 
FLAP expression did not differ from healthy controls but here we could identify a 
distinct sub group of patients (n=6/16) that expressed a significantly higher level of 
FLAP in comparison to the remaining patients as well as the controls. The lack of 
significance in the expression of cellular BLT1 between patients and healthy 
individuals was somewhat unexpected due to the almost total absence of immune cells 
in healthy muscle tissue. Thus we investigated whether skeletal muscle satellite cells 
might be the source of the BLT1 expression by staining consecutive tissue sections for 
BLT1 and PAX7 but we could not confirm any co-expression (unpublished data).  
 
 
Pro-inflammatory mediators are only partly affected by immunosuppressive 
treatment. 
Patients with polymyositis and dermatomyositis vary in their response to 
immunosuppressive treatment and the persistence of inflammatory markers in the 
muscle tissue of patients undergoing treatment has previously been reported.  
In the first study (paper I), IL-15 expression in muscle tissue was decreased after 
treatment in the whole group of patients. However, when the patients were divided into 
two subgroups based on the levels of IL-15 after immunosuppressive treatment almost 
half of the group still had elevated IL-15 compared with the healthy controls.  
The group with remaining high IL-15 expression had a poorer functional outcome both 
after the 8 months (median value) of treatment and also in the 5-year follow up. The 
outcome measures assessed, FI in the study and MMT in the long term follow-up, are 
not directly comparable but still give an indication of a potential distinction in recovery 
of the patients with persistent IL-15 expression. The CD28
null
 T frequency in muscle 
tissues of polymyositis and dermatomyositis patients is increased after 
immunosuppressive treatment (unpublished data), suggesting that IL-15 might 
contribute to the maintained dominance of CD28
null
 cytotoxic T cells in myositis 
muscle tissue. IL-15 might thus be a predictor of disease progression. 
 
The heterogeneity in disease mechanisms in myositis may be demonstrated by the 
importance of different pathways driving the inflammation. We identified another 
distinct subgroup through the expression of FLAP (paper III), a major regulator in the 
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LTB4 biosynthetic pathway. At the group level FLAP expression was down-regulated 
by treatment but after further analysis it was apparent that the decrease was only 
significant for patients with initially high FLAP levels. However, the treatment did not 
reduce the FLAP expression in parity to the levels observed in the subgroup of patients 
with low FLAP levels or healthy individuals. Whereas 5-LO and BLT1 expression in 
mononuclear cells were decreased after drug therapy, BLT1 expression in capillaries 
remained unaffected.  Interestingly, the effect of immunosuppressive treatment on 5-
LO and FLAP was different. The existing literature describes differential regulation of 
5-LO and FLAP and moreover of leukotriene synthesis, the latter being suggested to be 
linked to the tight regulation of FLAP by endogenous PGE2 [188]. 
 
In the PGE2 pathway (paper II) immunosuppressive treatment did have an effect on 
COX-2 as previously described [128] but was not able to down-regulate the expression 
of COX-1 or mPGES-1. The decreased COX-2 expression could be a result of the 
previously described anti-inflammatory effects of glucocorticoids or as an indirect 
effect of a reduced number of CD68
+
 macrophages. Targeting COX-2 through 
immunosuppressive treatment may interfere with the production of other prostaglandins 
involved in skeletal muscle regeneration. There are reports of mPGES-1 using COX-1-
generated PGH2 for PGE2 synthesis [189, 190]. The persisting expression of mPGES-1 
and COX-1 following immunosuppressive treatment in patients with polymyositis and 
dermatomyositis may maintain PGE2 production and contribute to the chronicity in 
these patients. However, the functional coupling between COX-1 and mPGES-1 on 
total PGE2 production in muscle tissue needs further investigation. 
 
Microsomal PGES-1 has received a lot of attention as a potential drug target in 
inflammatory diseases. There are selective inhibitors of either mPGES-1 expression or 
its enzyme activity [191-193]; however, the main issues that still need to be evaluated 
are whether the selective inhibition of mPGES-1 will lead to isolated PGE2 suppression 
or will interfere with the production of other prostaglandins.  
 
The COX and 5-LO pathways are highly interconnected and blocking different steps of 
one pathway can shunt the arachidonic acid metabolism to another pathway. Long-term 
COX inhibition can switch the eicosanoid production over to the 5-LO pathway [194] 
and LTB4 production and BLT1 signalling may in turn regulate the levels and stability 
of COX-2 mRNA [195]. There are some FLAP inhibitors in clinical trials for treating 
respiratory and cardiovascular disorders. By targeting FLAP in the upper part of the 
leukotriene pathway, the total leukotriene production will be affected. To avoid an 
undesired reduction in all downstream leukotrienes, inhibition of LTA4 hydrolase or the 
BLT-1 receptor could provide an even more specific target.  
 
Whether FLAP inhibitors, IL-15 or mPGES-1 blockade would work without major 
side-effects damaging the already afflicted skeletal muscle is yet to be explored. 
 
 
Detection of in vivo LTB4 levels and the consequence of a bout of acute exercise  
Based on the evidence of the up-regulated expression of the markers of LTB4 pathway 
in muscle tissues we wanted to compare the levels of LTB4 in thigh muscles in patients 
with polymyositis or dermatomyositis as well as in healthy controls. We detected LTB4 
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and could also reflect that a single bout of acute exercise elevated LTB4 levels in the 
patient group but not in the healthy controls. A further study with a larger cohort is 
needed to confirm this finding. However, the results may also indicate the existence of 
potential subgroups within these patients, similarly to the subgroups with different 
FLAP-expression. It is an appealing idea that the patients with the high in vivo LTB4 
levels also have elevated expression of FLAP and/or 5-LO, but this remains to be 
investigated.  
 
 
Fiber type transition and muscle atrophy in relation to muscle weakness & low 
endurance 
Even though patients with polymyositis or dermatomyositis respond to some extent to 
the immunosuppressive treatment, the majority still develop sustained disability [196] 
and have a reduced quality of life [197]. In patients with established disease and 
persisting muscle weakness it is a problematic assignment to discriminate between 
which aspects of muscle tissue morphology belongs to the myositis pathogenesis and 
which are likely to be related to a steroid myopathy.  
 
Previous studies from our research group have demonstrated a low proportion of type I 
fibers in the quadriceps muscle in patients with persisting weakness without signs of 
inflammation. When comparing patients in different state of disease and also treatment 
response in the chronic patients we determined that newly diagnosed patients with 
polymyositis or dermatomyositis exhibited a fiber type composition similar to that of 
healthy individuals. Thus the reduced endurance at disease onset is not a result of a 
lower proportion of oxidative fibers. Nonetheless, the predominance of glycolytic, less 
fatigue resistant type II fibers in the chronic phase might have an impact on muscle 
function.    
 
Low endurance or fatigue is the inability to maintain a certain force of power output in 
the muscle and even if this recorded shift in fiber types is recognized, the question is 
whether the change has an assessable function. Comparisons of fiber type distribution 
(paper IV) were made in different groups without the further strength that paired 
comparisons from individual follow-up data might have provided. In the cohort of 
patients selected for the microarray experiment (see below), we had routine ATPase 
staining performed by a pathologist. An analysis of the type I and type II compositions 
before and after immunosuppressive treatment in these patients revealed a significant 
change towards a more pronounced glycolytic fiber phenotype (unpublished data) 
confirming the data in paper IV. 
 
A second finding in paper IV was that no atrophy was evident in polymyositis and 
dermatomyositis patients after analysing fiber cross-sectional area in the different 
groups. These results are contradictory to previous publications that have suggested 
selective type II atrophy in patients with myositis. In addition, we found female 
myositis patients have a 20% smaller type II cross-sectional area compared to men, a 
feature mirroring muscle fiber composition in the healthy population. In order to avoid 
errors in incorporating measurements from the perifascicular areas where atrophic 
fibers are often seen, at least in dermatomyositis, we excluded those parts completely, 
but the results could have been strengthened further by measuring a higher number of 
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fibers. Our interpretation of these results is that there is a gender difference in muscle 
fiber CSA, particularly for type II fibers, in patients with polymyositis or 
dermatomyositis similar to that of the healthy population. This information could be 
valuable when interpreting muscle tissue sections in aspects of atrophy or muscle force-
generating questions in patients with myositis.  
 
 
Gene expression and tissue proteins manifestation after immunosuppressive 
treatment 
To investigate markers of inflammation and muscle tissue structure in a wider sense we 
studied gene expression in muscle tissue from newly diagnosed, untreated patients 
during the disease and treatment progress. In this experiment we included six patients 
(2 polymyositis, 4 dermatomyositis) with biopsies from m.vastus lateralis before and 
after a median of 10 (8-16) months of immunosuppressive treatment (unpublished 
data).  
Alterations in a number of genes coding for inflammatory responses and muscle tissue 
remodelling were observed. These results are not yet validated but might still give some 
indication on the different pathways of particular interest for our research group.  
Among the genes that were down-regulated following immunosuppressive treatment 
there was a high representation of HLA-genes encoding MHC I and II. The co-
stimulatory proteins CD80 and CD86 works together to prime T cells along with CD28, 
thus promoting activation and survival in the T cells. Among the cytokines we noted a 
partial down-regulation of IL-18 and the IL-18BP as well as IL-15. Genes involved in 
type I and type II IFN signaling were to a large extent affected by immunosuppressive 
treatment. A variety of chemokine ligands and receptors were also down-regulated, 
both α-chemokines such as CXCL10 and CXCL11 and the β-chemokines CCL2, CCL5 
and CCR2. ICAM-1 was also partially down-regulated after immunosuppressive 
treatment.  In the genes related to the leukotriene pathway there was no noteworthy 
alteration in prostaglandin reductase 1, which can inactivate LTB4. Prostaglandin E2 
receptors EP3 and EP4 were up- and down-regulated respectively.  
 
This data provides indications that the gene transcription of a number of pro-
inflammatory genes in skeletal muscle tissue of patients with polymyositis and 
dermatomyositis goes down during immunosuppressive treatment. Our interpretation of 
these results is that immunosuppressive treatment may have an impact on skeletal 
muscle inflammation but that the local milieu could be accountable for the preserved 
expression of inflammatory cells and mediators in polymyositis and dermatomyositis.  
 
When we analyzed the genes involved in muscle tissue structure we noted that the fast-
twitch muscle protein α-actinin 3 and vinculin were both up-regulated. The negative 
regulator of muscle growth myostatin was up-regulated while the myostatin regulating 
protease bone morphologic protein 1 (BMP1) was down after treatment. Ras associated 
with diabetes (RRAD) is involved early in skeletal muscle regeneration [198] and was 
found to be down-regulated after the drug therapy. The GR co-chaperone protein 
FK506 binding protein 5 (FKBP5), recently suggested to be involved in fiber type 
transition [199], was up regulated in response to treatment. Further, myosin heavy 
chain 4 (MYH4) coding for fast-twitch fibers was up-regulated. Myosin binding protein 
H (MYBPH) was strongly down-regulated. MYBPH is principally associated with fast 
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twitch fibers but according to others it may also represent an early sign of regeneration 
[200]. These transcriptional alterations in muscle tissue from patients with polymyositis 
and dermatomyositis could be interpreted as ongoing muscle tissue remodeling. 
 
These results need to be further validated. 
 
 
 
9.1 METHODOLOGICAL CONSIDERATIONS 
Handling small number of patients for a rare disease raises questions of 
representativeness and makes the selection criteria quite broad. This can be rather 
sensitive to changes in time points for the longitudinal follow-up and when an outcome 
measure is lacking the material diminishes further. In addition, the patient material was 
collected over a long period of time (1998-2004) and this result in a discrepancy in the 
clinical data available. The IMACS outcome measures were not taken in use until 2003. 
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10 CONCLUSIONS 
In this thesis, some novel molecular features in polymyositis and dermatomyositis have 
been investigated. The pro-inflammatory cytokine IL-15 and its receptor, markers in 
both the PGE2 and LTB4 pathways, as well as the composition of oxidative and 
glycolytic muscle fibers in patients at diagnosis and in a later phase of disease have all 
been examined and reported. Whereas IL-15, COX-1, mPGES-1 and the LTB4 pathway 
might be involved as early markers of myositis chronicity, the low proportion of 
oxidative muscle fibers is not a marker of disease in early myositis but instead this 
feature appears to develop over time. 
 
. 
 IL-15 and IL-15Rα were overexpressed in polymyositis and dermatomyositis 
compared to healthy individuals and there was a negative correlation between 
baseline IL-15 and muscle function improvement. A defined subgroup did not 
respond to immunosuppressive treatment accompanied with a lesser functional 
outcome.   
 
 The PGE2 pathway was up-regulated in patients compared to healthy 
individuals and immunosuppressive treatment only gave partial down- 
regulation of the pathway. 
 
 Our results revealed an elevated LTB4 pathway in polymyositis and 
dermatomyositis. Drug therapy was only able to partially suppress LTB4 
production. 
 
 We could detect in vitro LTB4 in myositis patients and a bout of cycling 
significantly increased the levels. 
 
 A low proportion of oxidative muscle fibers was not present in untreated 
patients at the time point of diagnosis. A skewed fiber type composition was 
thus excluded as a contributing factor to the low muscle endurance and 
pathogenesis in early disease.  
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11 FUTURE PERSPECTIVES & CONCLUDING REMARKS 
 
It would be valuable to be able to separate potential glucocorticoid effects on myositis 
skeletal muscle from the inflammatory myopathy. Therefore a robust animal model in 
which a straightforward comparison between a glucocorticoid-treated IIM condition 
and an untreated group could be performed would be of interest.  
Muscle biopsies are a gold mine of information and much data can be retrieved from 
multiple repeated biopsies, both to see very early alterations and to cover the prolonged 
disease process.  
The microdialysis thechnique, and thereby an in vivo method that works in patients 
with polymyositis or dermatomyositis provides possibilities to investigate both 
physiologically and pathologically processes in the skeletal muscle. Here more studies 
evaluating inflammatory or metabolic responses could be performed either under 
resting conditions or under exercise induced stress in myositis patients. 
With these muscle biopsies and dialysis perfusates available, methods providing large 
scale data could be assessed and this information could serve as a library in which new 
possible pathways important in polymyositis and dermatomyositis could be explored. 
 
To me, the major challenge when investigating polymyositis and dermatomyositis 
patients has been to figure out a way to distinguish between which clinical and 
molecular features are caused by the disease per se, or by on-going normal or failed 
muscle regeneration or profound glucocorticoid treatment provocation. In my opinion, 
the complexity of the polymyositis and dermatomyositis diseases arises from an 
inflammatory target organ that grows and regenerates with inflammation. The Janus 
face of each immune cell and the dual features of every cytokine, known or just not 
discovered yet, are hurdles in the search for an optimal drug treatment.  
Investigating differential expressions will not say anything about the actual function of 
the end protein being synthesized, but will give essential pointers of where to look and 
what to further investigate.  
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12 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Polymyosit och dermatomyosit (myosit) är sjukdomar som innefattar kronisk 
inflammation i skelettmuskulaturen. Patienterna upplever gradvis muskelsvaghet och 
sämre uthållighet som inverkar på det dagliga livet. Förutom muskelinflammationen 
löper patienterna även risk att utveckla lungsjukdom, hjärtproblem och cancer. 
Patienter med dermatomyosit har dessutom alltid karaktäristiska hudutslag. 
Myositpatienter behandlas inledningsvis med höga doser kortison som gradvis trappas 
ned och kombineras med ytterligare immundämpande medicin. Trots aggressiv 
behandling blir patienterna ofta inte helt återställda utan känner av muskelsvaghet även 
om inflammationen i musklerna minskat.  
I min avhandling har jag undersökt muskelvävnad från patienter med 
polymyosit eller dermatomyosit. Muskeln är tagen med biopsi vid diagnostillfället då 
patienterna ännu inte fått någon immundämpande behandling samt vid ett 
uppföljningstillfälle efter ungefär 8 månaders medicinering. Förutom muskelbiopsier 
har vi samlat vätska inifrån muskeln på patienterna med microdialys, där man via en 
kateter sköljer ut molekyler från området mellan muskelfiberrna (=avlånga 
muskelceller). Vi har även tagit biopsier och gjort microdialys på frivilliga friska 
personer för att jämföra med våra patienter. 
I dessa prover har jag sedan undersökt molekyler i olika inflammatoriska 
signalvägar som kan tänkas ligga bakom muskelsvagheten. Dessutom har jag försökt 
fastställa om sammansättningen av snabba och långsamma muskelfiber är en 
bidragande orsak. För dessa undersökningar färgas muskelns protein, oftast med 
antikroppar som binder specifikt till den molekyl som eftersöks. I avhandlingen 
lyckades vi först fastställa att myositpatienterna hade höga värden av signalmolekylen 
IL-15 och dess receptor. IL-15 kan aktivera de immunceller som kallas T celler och 
’elda på’ inflammationen samt göra T cellerna väldigt giftiga för muskelfiberrna. Den 
immundämpande behandlingen hade ingen verkan på IL-15 i 1/3 av patienterna. Sedan 
kunde vi även påvisa att proteiner som tillverkar prostaglandin E2 (PGE2) och 
leukotrien B4 (LTB4), som båda är signalmolekyler av fettsyror, i högre grad finns i 
myositpatienters muskler jämfört med friska personer. PGE2 och LTB4 upprätthåller 
inflammation genom att de attraherar immunceller som cirkulerar i blodet att ta sig ut 
till musklerna. Även dessa signalvägar visade sig bara delvis nedregleras av 
medicineringen. Mikrodialysproverna visade att patienterna hade lika mycket LTB4 
som friska under vila men efter ett cykelprov hade patienterna högre nivåer LTB4 vilket 
kan bero på att de har en större andel av proteinerna som behövs under tillverkningen.  
Tidigare har man sett att myositpatienter har en låg andel långsamma, uthålliga 
muskelfiber och trott att det möjligen bidrog till muskelsvagheten. Då vi jämförde 
obehandlade patienter med patienter som under lång tid fått behandling kunde vi se att 
de obehandlade patienterna inte skiljde sig från friska. Därmed avskrev vi 
fiberfördelningen som orsak till muskelsvaghet, i alla fall i ett tidigt sjukdomsstadie.  
 Slutsatserna jag dragit av resultaten är att dagens immundämpande 
behandling inte är tillräcklig för att hämma muskelinflammationen hos många som har 
myosit och att det finns undergrupper ibland patienterna där de olika signalvägarna har 
olika stor betydelse för sjukdomsbilden. Kanske kan man behandla de olika 
signalvägarna individuellt men IL-15, PGE2 och LTB4 har samtliga egenskaper som 
behövs vid vanlig muskelförnyelse vilket gör behandlingssituationen mer komplex. 
 34 
13 ACKNOWLEDGEMENTS 
 
Walking the crooked line of life has taken me on a journey I would never have 
imagined.  The people who joined me for the ride, some for parts of it and others all the 
way are acknowledged below.  
 
To my supervisor Ingrid, I consider myself very lucky to have you as my supervisor. 
The things you have taught me about research, teamwork, patients and most important 
about myself are absolutely invaluable. Thank you for taking me on board and 
believing in me. You are the ultimate role model for women in science – you are in 
persona a highly skilled professor, medical doctor, woman, friend and human being at 
the same time. Never stop being a scientific rock star! 
 
My co-supervisor Marina, not only have you taught me every practical step I’ve taken 
during my education, you have also been my biggest security knowing that you always 
give me your true opinion no matter what the question is. I’ve always trusted your 
honesty and felt very safe knowing that you look after my interest. Our friendship has 
made my road less rocky and your view on life and what’s really important will always 
inspire me. 
 
These two fantastic women have made marks both in science and in my life and I am 
forever thankful for them chaperoning me through this new world. 
 
Lars, thank you for providing such an open and encouraging work environment. For 
always being so genuinely interested, forthcoming and up to date on everything going 
on. I am very proud to have been given the opportunity to belong to your department. 
 
Ralf, thank you for accepting the mentorship, I knew you were a top choice! I have 
appreciated all our talks, lunches, high and low, inspirational science discussions and 
personal logistics. You’ve always been just an email away, always positive and ready 
to help me make sense of it all. 
 
Mona, lovely Mona – a colourful explosion of exploration. Such genuine interest and 
curiosity to understand everything and everyone around you. You have become a very 
dear friend and I am happy that we’ve shared our journeys. I will never let you go. 
 
Eva dearest, there has been absolutely no time when you haven’t been there for me, 
work wise and personally.  I can never reciprocate what you have done for me but I do 
try to be less sloppy in order to make your life easier. And since I obviously don’t 
always succeed, I occasionally bake cookies for you. 
 
Past and current members of the myositis group; Cissi, a special thanks to you, the one 
who got me into this place. Sevim, Thanks for all your wisdom and pep talks. You are 
true fighter! Thank you Maryam for your endless generosity and for sharing your 
lovely family.  Li, Helene and Malin; wonderful ladies and wonderful friends. Thanks 
for all great laughs, scientific and personal discussions. Mei, thanks for being such an 
important addition to our group. Your warm personality and hunger for knowledge is 
   35 
inspiring. Jayesh; I got such a dear friend when you joined our group.  Christina, to 
my knowledge the best nurse in the world. I am so touched by your big, warm heart 
embracing all your patients and coworkers. Lara, Inka & Andreas, always with a 
smile and a kind word. Paulius, let’s travel some more!  John, I enjoy having you at 
my shoulder. Anna, my friend, let’s keep it that way forever.  
 
VIP persons who carried me through these years; Kära Marianne, nu får vi mer tid att 
prata igen. Gunnel, tack för att du alltid reder ut allt och aldrig förebrår mig. Susanne, 
trollar med knäna och alltid med ett skratt. Veronica, ser fram emot mer party med dig. 
Uffe, troget hjälper du mig när jag gång på gång behöver inloggningshjälp – det är 
alltid trevligt att sitta hos dig. 
 
The eicosanoid people; Per-Johan, you are such a blast of ideas one can hardly defend 
oneself. A very fun and challenging addition of testosterone to my work.  Sven, I will 
never forget that you let my 1-year old taste nutella for breakfast. Fortunately you have 
many other lovable features. Karina, even though we’ve mostly been pregnant we’ve 
still found times to work together and become friends.  Helena, Elena, Karin & 
Hanna; I’m clueless of your work but you’re such great gal’s and there’s so much of 
other fun stuff we can talk about. Patrick, I cannot thank you enough for all the support 
you provided. Thanks for all nice chats over the bench. Ever so lovely Joan, thank you 
for all the help, support and great times over gels and membranes. I had so much fun 
this last months doing experiments side by side with you.  
 
For being wonderful female role models and just exeptionally kind people; Vivi, Marie 
WH, Helena H, Anca and Eva Jansson.  
 
And not to forget the male role models; Leonid, all you have to do is smile and it feels 
comforting & Bob; thank you for always being available with kind advice and practical 
help.  
 
Shankar – you are pure sunshine and provide balance to my life. I hope that all good 
things in life will come to you. Lasse for all your help and wise input – and for always 
blaming the hardware/software/IT department etc. instead of me. Viole, Heidi, Hanna, 
Hulda, Peter, Therese Ö, Lotta, Karine, Eva J, Vilja, Sukanya, Mona, Kristina, Akilan, 
Vivek, Srini, Marie Westman, Eva Melin, Dimitrios, Olga, Therese W, Emeli, Marcus, 
Aurelie, Alex, Omri, Nånnis, Jessi, Magda, Mikael...oh, oh, oh, I know I am forgetting 
some. I’ve been around since 2005 so I have to sum it up; 
thanks to everyone in the Rheumatology and Neuroimmunology groups. 
 
Thanks to all my new friends at K1; Thomas, Christina, Elisabeth, Birgitta & Susanne. 
Ni får mig att trivas I ‘köket’ och er forskning fascinerar mig. 
 
Gustavo, my great teacher and friend both while working in DC and now here at 
CMM. I will always be grateful for you making me feel less alone over there. My other 
dear DC friends; Yetrib, Javad, Bill and Andrea.  Raju; I am happy that I got the 
opportunity to work with you and I am honored that you are my friend. Eric Hoffmann, 
thank you for open up your lab for me to visit. It was a great adventure. 
 
 36 
Alla mina nuttisar som såg till att jag klarade tentorna och hade roligt under tiden;  
Ann, Burre, Sofia, Sevim, Susanne, Lisa, Sofie, Caroline, Carolina, Per & William 
 
My in-law family; Ingrid, Veronica, Bengt, Jonas and Mattias with families – min 
förlängda familj. Jag är så glad att jag fick er på köpet och sätter stort värde på att ha er 
i mitt liv. 
 
My dearest and oldest friend Jenny. Who would have known that the two of us starting 
to play soccer together at age 6 would end up PhDs with our children playing together 
on the opposite side of the country? I love you for never letting go and for bringing 
Sergio, Felicia and Marta into my life.   
 
Friends I carry around in my heart always; Niklas, Martin, Maria, Linda, Stefan, Dick, 
Mats & Christian. 
 
Meine Oma, words are not enough to express the impact this incredible woman has 
had on my life. I know how proud she would have been if she’d still been around. I 
miss you so much and I try to cherish the memory of you in everything that I do. 
 
Mamma Maria och pappa Arne, allra käraste syster Anne och storebror Peter för att 
ni gjort mig till den jag är. 
 
Min Henrik. Tack för ditt oerhörda stöd och din tro på mig. Your love makes me 
wanna be the best person I can, and allows me to be the person I usually end up being. 
Tack för ditt ändlösa tålamod och för våra älskade bus-loppor, Alma and Inez, who 
helps me to put things in perspective and teaches me more in one afternoon than 4 years 
of postgraduate studies.  My love for you is eternal. 
 
 
   37 
14 REFERENCES 
 
1. Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: 
epidemiology, classification, and diagnostic criteria. Rheum Dis Clin N Am. 2002 Nov; 
28(4):723-+. 
2. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification 
of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful 
homogeneous patient groups. Medicine. 1991 Nov; 70(6):360-374. 
3. Dalakas M. Polymyositis, dermatomyositis and inclusion-body myositis. 
N Engl J Med. 1991; 325(21):1487-1498. 
4. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two 
parts). New England Journal of Medicine. 1975; 292(8):403-407. 
5. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). 
New England Journal of Medicine. 1975; 292(7):344-347. 
6. Plotz PH, Rider LG, Targoff IN, et al. NIH conference. Myositis: 
immunologic contributions to understanding cause, pathogenesis, and therapy. Annals 
of internal medicine. 1995 May 1; 122(9):715-724. 
7. Marie I, Hatron PY, Hachulla E, et al. Pulmonary involvement in 
polymyositis and in dermatomyositis. The Journal of rheumatology. 1998 Jul; 
25(7):1336-1343. 
8. Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and 
dermatomyositis. Current opinion in rheumatology. 2005 Nov; 17(6):701-706. 
9. Haupt HM, Hutchins GM. The heart and cardiac conduction system in 
polymyositis-dermatomyositis: a clinicopathologic study of 16 autopsied patients. Am J 
Cardiol. 1982 Nov; 50(5):998-1006. 
10. Gonzalez-Lopez L, Gamez-Nava JI, Sanchez L, et al. Cardiac 
manifestations in dermato-polymyositis. Clinical and experimental rheumatology. 1996 
Jul-Aug; 14(4):373-379. 
11. Zahr ZA, Baer AN. Malignancy in myositis. Current rheumatology 
reports. 2011 Jun; 13(3):208-215. 
12. Aggarwal R, Oddis CV. Paraneoplastic Myalgias and Myositis. Rheum 
Dis Clin N Am. 2011 Nov; 37(4):607-+. 
13. Spiera R, Kagen L. Extramuscular manifestations in idiopathic 
inflammatory myopathies. Current opinion in rheumatology. 1998 Nov; 10(6):556-561. 
14. Santmyire-Rosenberger B, Dugan EM. Skin involvement in 
dermatomyositis. Current Opinion in Rheumatology. 2003 Nov; 15(6):714-722. 
15. Dorph C, Englund P, Nennesmo I, et al. Signs of inflammation in both 
symptomatic and asymptomatic muscles from patients with polymyositis and 
dermatomyositis. Annals of the Rheumatic Diseases. 2006 Dec; 65(12):1565-1571. 
16. Coley W, Rayavarapu S, Nagaraju K. Role of non-immune mechanisms 
of muscle damage in idiopathic inflammatory myopathies. Arthritis research & 
therapy. 2012 Apr 27; 14(2):209. 
17. Nyberg P, Wikman AL, Nennesmo I, et al. Increased expression of 
interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive 
polymyositis and dermatomyositis. The Journal of rheumatology. 2000 Apr; 27(4):940-
948. 
18. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the 
endoplasmic reticulum stress response in autoimmune myositis - Potential role in 
muscle fiber damage and dysfunction. Arthritis and Rheumatism. 2005 Jun; 
52(6):1824-1835. 
 38 
19. Salomonsson S, Grundtman C, Zhang SJ, et al. Upregulation of Mhc 
Class I in Transgenic Mice Results in Reduced Force-Generating Capacity in Slow-
Twitch Muscle. Muscle & Nerve. 2009 May; 39(5):674-682. 
20. Grundtman C, Lundberg IE. Vascular involvement in the pathogenesis of 
idiopathic inflammatory myopathies. Autoimmunity. 2009; 42(7):615-626. 
21. Cid MC, Grau JM, Casademont J, et al. Leucocyte/endothelial cell 
adhesion receptors in muscle biopsies from patients with idiopathic inflammatory 
myopathies (IIM). Clin Exp Immunol. 1996 Jun; 104(3):467-473. 
22. Alger HM, Rayavarapu S, Nagaraju K. Measurement of Activation of the 
Endoplasmic Reticulum Stress Response in Autoimmune Myositis. Method Enzymol. 
2011; 489:207-225. 
23. Estruch R, Grau JM, Fernandez-Sola J, et al. Microvascular changes in 
skeletal muscle in idiopathic inflammatory myopathy. Human pathology. 1992 Aug; 
23(8):888-895. 
24. Grundtman C, Tham E, Ulfgren AK, et al. Vascular Endothelial Growth 
Factor Is Highly Expressed in Muscle Tissue of Patients With Polymyositis and 
Patients With Dermatomyositis. Arthritis Rheum. 2008 Oct; 58(10):3224-3238. 
25. Probst-Cousin S, Neundorfer B, Heuss D. Microvasculopathic 
neuromuscular diseases: Lessons from hypoxia-inducible factors. Neuromuscular 
Disord. 2010 Mar; 20(3):192-197. 
26. Emsliesmith AM, Engel AG. Microvascular Changes in Early and 
Advanced Dermatomyositis - a Quantitative Study. Ann Neurol. 1990 Apr; 27(4):343-
356. 
27. Mastaglia FL, Phillips BA, Zilko P. Treatment of inflammatory 
myopathies. Muscle & nerve. 1997 Jun; 20(6):651-664. 
28. Oddis CV. Therapy of inflammatory myopathy. Rheumatic diseases 
clinics of North America. 1994 Nov; 20(4):899-918. 
29. Revollo JR, Cidlowski JA. Mechanisms generating diversity in 
glucocorticoid receptor signaling. Annals of the New York Academy of Sciences. 2009 
Oct; 1179:167-178. 
30. Hayden MS, Ghosh S. NF-kappa B, the first quarter-century: remarkable 
progress and outstanding questions. Gene Dev. 2012 Feb 1; 26(3):203-234. 
31. Hayden MS, Ghosh S. NF-kappa B in immunobiology. Cell Res. 2011 
Feb; 21(2):223-244. 
32. Herrmann O, Baumann B, de Lorenzi R, et al. IKK mediates ischemia-
induced neuronal death. Nature medicine. 2005 Dec; 11(12):1322-1329. 
33. Barakat W, Herrmann O, Baumann B, et al. NF-kappa B induces 
PGE(2)-synthesizing enzymes in neurons. N-S Arch Pharmacol. 2009 Aug; 
380(2):153-160. 
34. Sanchez-Galan E, Gomez-Hernandez A, Vidal C, et al. Leukotriene B4 
enhances the activity of nuclear factor-kappa B pathway through BLT1 and BLT2 
receptors in atherosclerosis. Cardiovasc Res. 2009 Jan 1; 81(1):216-225. 
35. Lee SJ, Kim CE, Seo KW, et al. HNE-induced 5-LO expression is 
regulated by NF-kappa B/ERK and Sp1/p38 MAPK pathways via EGF receptor in 
murine macrophages. Cardiovasc Res. 2010 Nov; 88(2):352-359. 
36. Peterson JM, Bakkar N, Guttridge DC. NF-kappa B SIGNALING IN 
SKELETAL MUSCLE HEALTH AND DISEASE. Curr Top Dev Biol. 2011; 96:85-
119. 
37. Creus KK, De Paepe B, De Bleecker JL. Idiopathic inflammatory 
myopathies and the classical NF-kappaB complex: current insights and implications for 
therapy. Autoimmunity reviews. 2009 Jun; 8(7):627-631. 
   39 
38. Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of 
functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity 
in some diseases, and implications for the pathogenesis of the different inflammatory 
myopathies. Human pathology. 1986 Jul; 17(7):704-721. 
39. Tournadre A, Miossec P. Interleukin-17 in inflammatory myopathies. 
Curr Rheumatol Rep. 2012 Jun; 14(3):252-256. 
40. Fasth AE, Dastmalchi M, Rahbar A, et al. T cell infiltrates in the muscles 
of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. 
J Immunol. 2009 Oct 1; 183(7):4792-4799. 
41. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage 
activation. Nature reviews Immunology. 2008 Dec; 8(12):958-969. 
42. Gordon S. Alternative activation of macrophages. Nature Reviews 
Immunology. 2003 Jan; 3(1):23-35. 
43. Moyer AL, Wagner KR. Regeneration versus fibrosis in skeletal muscle. 
Current opinion in rheumatology. 2011 Nov; 23(6):568-573. 
44. Brunelli S, Rovere-Querini P. The immune system and the repair of 
skeletal muscle. Pharmacological research : the official journal of the Italian 
Pharmacological Society. 2008 Aug; 58(2):117-121. 
45. Tidball JG, Villalta SA. Regulatory interactions between muscle and the 
immune system during muscle regeneration. Am J Physiol-Reg I. 2010 May; 
298(5):R1173-R1187. 
46. Zhang L, Dong Y, Cheng J, et al. Role of integrin-beta3 protein in 
macrophage polarization and regeneration of injured muscle. J Biol Chem. 2012 Feb 
24; 287(9):6177-6186. 
47. Englund P, Nennesmo I, Klareskog L, et al. Interleukin-1alpha expression 
in capillaries and major histocompatibility complex class I expression in type II muscle 
fibers from polymyositis and dermatomyositis patients: important pathogenic features 
independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum. 2002 Apr; 
46(4):1044-1055. 
48. Korotkova M, Helmers SB, Loell I, et al. Effects of immunosuppressive 
treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression 
in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis. 
2008 Nov; 67(11):1596-1602. 
49. de Padilla CM, Reed AM. Dendritic cells and the immunopathogenesis of 
idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2008 Nov; 20(6):669-674. 
50. Grundtman C, Malmstrom V, Lundberg IE. Immune mechanisms in the 
pathogenesis of idiopathic inflammatory myopathies. Arthritis research & therapy. 
2007; 9(2):208. 
51. Pedrol E, Grau JM, Casademont J, et al. Idiopathic Inflammatory 
Myopathies - Immunohistochemical Analysis of the Major Histocompatibility Complex 
Antigen Expression, Inflammatory Infiltrate Phenotype and Activation Cell Markers. 
Clin Neuropathol. 1995 May-Jun; 14(3):179-184. 
52. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear 
cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis. Ann 
Neurol. 1988 Feb; 23(2):168-173. 
53. De Rossi M, Bernasconi P, Baggi F, et al. Cytokines and chemokines are 
both expressed by human myoblasts: possible relevance for the immune pathogenesis 
of muscle inflammation. Int Immunol. 2000 Sep; 12(9):1329-1335. 
54. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal 
muscle as a secretory organ. Nature reviews Endocrinology. 2012 Apr 3. 
55. Lundberg I KA, Alexanderson H, Patarroyo M. Decreased expression of 
interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue 
 40 
following corticosteroid treatment in patients with polymyositis and dermatomyositis. 
Arthritis & Rheumatism. 2000; 43(2):336-348. 
56. Chevrel G, Granet C, Miossec P. Contribution of tumour necrosis factor 
alpha and interleukin (IL) 1 beta to IL6 production, NF-kappa B nuclear translocation, 
and class I MHC expression in muscle cells: in vitro regulation with specific cytokine 
inhibitors. Annals of the Rheumatic Diseases. 2005 Sep; 64(9):1257-1262. 
57. Mantovani A, Bussolino F, Dejana E. Cytokine Regulation of 
Endothelial-Cell Function. Faseb J. 1992 May; 6(8):2591-2599. 
58. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996 
Mar 15; 87(6):2095-2147. 
59. Morel JCM, Park CC, Zhu K, et al. Signal transduction pathways 
involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell 
adhesion molecule-1 expression. J Biol Chem. 2002 Sep 20; 277(38):34679-34691. 
60. Dai SM, Matsuno H, Nakamura H, et al. Interleukin-18 enhances 
monocyte tumor necrosis factor alpha and interleukin-1 beta production induced by 
direct contact with T lymphocytes - Implications in rheumatoid arthritis. Arthritis and 
Rheumatism. 2004 Feb; 50(2):432-443. 
61. Dinarello CA. Interleukin-18, a proinflammatory cytokine. Eur Cytokine 
Netw. 2000 Sep; 11(3):483-486. 
62. Tucci M, Quatraro C, Dammacco F, et al. Interleukin-18 overexpression 
as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp 
Immunol. 2006 Oct; 146(1):21-31. 
63. Tucci M, Quatraro C, Dammacco F, et al. Increased IL-18 production by 
dendritic cells in active inflammatory myopathies. Ann Ny Acad Sci. 2007; 1107:184-
192. 
64. Goetz FW, Planas JV, MacKenzie S. Tumor necrosis factors. Dev Comp 
Immunol. 2004 May 3; 28(5):487-497. 
65. Nagaraju K, Raben N, Merritt G, et al. A variety of cytokines and 
immunologically relevant surface molecules are expressed by normal human skeletal 
muscle cells under proinflammatory stimuli. Clin Exp Immunol. 1998 Sep; 113(3):407-
414. 
66. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of 
disease flares in an open pilot study of infliximab in patients with refractory 
inflammatory myopathies. Annals of the Rheumatic Diseases. 2008 Dec; 67(12):1670-
1677. 
67. Dold S, Justiniano ME, Marquez J, et al. Treatment of early and 
refractory dermatomyositis with infliximab: a report of two cases. Clinical 
Rheumatology. 2007 Jul; 26(7):1186-1188. 
68. Anandacoomarasamy A, Howe G, Manolios N. Advanced refractory 
polymyositis responding to infliximab. Rheumatology. 2005 Apr; 44(4):562-563. 
69. Tezak Z, Hoffman EP, Lutz JL, et al. Gene expression profiling in 
DQA1*0501(+) children with untreated dermatomyositis: A novel model of 
pathogenesis. Journal of Immunology. 2002 Apr 15; 168(8):4154-4163. 
70. Schmidt J, Barthel K, Wrede A, et al. Interrelation of inflammation and 
APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. 
Brain. 2008 May; 131:1228-1240. 
71. Baird GS, Montine TJ. Multiplex immunoassay analysis of cytokines in 
idiopathic inflammatory myopathy. Arch Pathol Lab Med. 2008 Feb; 132(2):232-238. 
72. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-
mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005 May; 
57(5):664-678. 
   41 
73. Greenberg. Molecular profiles of inflammatory myopathies (vol 59, pg 
1170, 2002). Neurology. 2004 Feb 24; 62(4):678-678. 
74. Greenberg SA, Higgs BW, Morehouse C, et al. Relationship between 
disease activity and type 1 interferon- and other cytokine-inducible gene expression in 
blood in dermatomyositis and polymyositis. Genes and immunity. 2012 Apr; 13(3):207-
213. 
75. Walsh RJ, Kong SW, Yao Y, et al. Type I interferon-inducible gene 
expression in blood is present and reflects disease activity in dermatomyositis and 
polymyositis. Arthritis Rheum. 2007 Nov; 56(11):3784-3792. 
76. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional 
alarmin driving autoimmune and inflammatory disease. Nature reviews Rheumatology. 
2012 Apr; 8(4):195-202. 
77. Ulfgren AK, Grundtman C, Borg K, et al. Down-regulation of the 
aberrant expression of the inflammation mediator high mobility group box 
chromosomal protein 1 in muscle tissue of patients with polymyositis and 
dermatomyositis treated with corticosteroids. Arthritis and Rheumatism. 2004 May; 
50(5):1586-1594. 
78. Harris HE, Andersson U, Pisetsky DS. HMGB1: A multifunctional 
alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012 Apr; 
8(4):195-202. 
79. Sehgal PB, Wang L, Rayanade R, et al. Interleukin-6-type cytokines. 
Interleukin-6 Type Cytokines. 1995; 762:1-14. 
80. Hirano T. The Biology of Interleukin-6. Chem Immunol. 1992; 51:153-
180. 
81. Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in 
muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J 
Neuroimmunol. 1995 Dec; 63(1):9-16. 
82. Lundberg I, Ulfgren AK, Nyberg P, et al. Cytokine production in muscle 
tissue of patients with idiopathic inflammatory myopathies. Arthritis and Rheumatism. 
1997 May; 40(5):865-874. 
83. Carson WE, Giri JG, Lindemann MJ, et al. Interleukin (Il)-15 Is a Novel 
Cytokine That Activates Human Natural-Killer-Cells Via Components of the Il-2 
Receptor. Journal of Experimental Medicine. 1994 Oct 1; 180(4):1395-1403. 
84. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to 
human disease. Blood. 2001 Jan 1; 97(1):14-32. 
85. Alonso-Arias R, Moro-Garcia MA, Vidal-Castineira JR, et al. IL-15 
preferentially enhances functional properties and antigen-specific responses of 
CD4+CD28(null) compared to CD4+CD28+ T cells. Aging cell. 2011 Oct; 10(5):844-
852. 
86. Chiu WK, Fann M, Weng NP. Generation and growth of CD28nullCD8+ 
memory T cells mediated by IL-15 and its induced cytokines. J Immunol. 2006 Dec 1; 
177(11):7802-7810. 
87. Alonso-Arias R, Moro-Garcia MA, Vidal-Castineira JR, et al. IL-15 
preferentially enhances functional properties and antigen-specific responses of 
CD4+CD28(null) compared to CD4+CD28+T cells. Aging Cell. 2011 Oct; 10(5):844-
852. 
88. Chiu WK, Fann M, Weng NP. Generation and growth of 
CD28(null)CD8(+) memory T cells mediated by IL-15 and its induced cytokines. 
Journal of Immunology. 2006 Dec 1; 177(11):7802-7810. 
89. Suzuki J, Morimoto S, Amano H, et al. Serum levels of interleukin 15 in 
patients with rheumatic diseases. Journal of Rheumatology. 2001 Nov; 28(11):2389-
2391. 
 42 
90. Sugiura T, Harigai M, Kawaguchi Y, et al. Increased IL-15 production of 
muscle cells in polymyositis and dermatomyositis. Int Immunol. 2002 Aug; 14(8):917-
924. 
91. Sugiura T, Kawaguchi Y, Harigai M, et al. Increased CD40 expression on 
muscle cells of polymyositis and dermatomyositis: Role of CD40-CD40 ligand 
interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. 
Journal of Immunology. 2000 Jun 15; 164(12):6593-6600. 
92. Pedersen BK. Muscles and their myokines. J Exp Biol. 2011 Jan; 
214(2):337-346. 
93. Warren GL, Hulderman T, Jensen N, et al. Physiological role of tumor 
necrosis factor alpha in traumatic muscle injury. Faseb J. 2002 Oct; 16(12):1630-1632. 
94. De Mori R, Straino S, Di Carlo A, et al. Multiple effects of high mobility 
group box protein 1 in skeletal muscle regeneration. Arterioscl Throm Vas. 2007 Nov; 
27(11):2377-2383. 
95. Sorci G, Riuzzi F, Arcuri C, et al. Amphoterin stimulates myogenesis and 
counteracts the antimyogenic factors basic fibroblast growth factor and S100B via 
RAGE binding. Molecular and cellular biology. 2004 Jun; 24(11):4880-4894. 
96. Riuzzi F, Sorci G, Donato R. The amphoterin (HMGB1)/receptor for 
advanced glycation end products (RAGE) pair modulates myoblast proliferation, 
apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE 
in L6 myoblasts results in tumor formation in vivo. J Biol Chem. 2006 Mar 24; 
281(12):8242-8253. 
97. Gray SR, Kamolrat T. The effect of exercise induced cytokines on insulin 
stimulated glucose transport in C2C12 cells. Cytokine. 2011 Aug; 55(2):221-228. 
98. Zanchi NE, Lira FS, de Siqueira Filho MA, et al. Chronic low 
frequency/low volume resistance training reduces pro-inflammatory cytokine protein 
levels and TLR4 mRNA in rat skeletal muscle. European journal of applied 
physiology. 2010 Aug; 109(6):1095-1102. 
99. Tamura Y, Watanabe K, Kantani T, et al. Upregulation of circulating IL-
15 by treadmill running in healthy individuals: is IL-15 an endocrine mediator of the 
beneficial effects of endurance exercise? Endocrine journal. 2011; 58(3):211-215. 
100. Pistilli EE, Bogdanovich S, Garton F, et al. Loss of IL-15 receptor alpha 
alters the endurance, fatigability, and metabolic characteristics of mouse fast skeletal 
muscles. The Journal of clinical investigation. 2011 Aug; 121(8):3120-3132. 
101. De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and 
chemokines in idiopathic inflammatory myopathies. Current opinion in rheumatology. 
2009 Nov; 21(6):610-616. 
102. Civatte M, Bartoli C, Schleinitz N, et al. Expression of the beta 
chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory 
myopathies. Neuropathology and applied neurobiology. 2005 Feb; 31(1):70-79. 
103. Figarella-Branger D, Civatte M, Bartoli C, et al. Cytokines, chemokines, 
and cell adhesion molecules in inflammatory myopathies. Muscle & nerve. 2003 Dec; 
28(6):659-682. 
104. Liu Y, Shaw SK, Ma S, et al. Regulation of leukocyte transmigration: cell 
surface interactions and signaling events. J Immunol. 2004 Jan 1; 172(1):7-13. 
105. Jain A, Sharma MC, Sarkar C, et al. Increased expression of cell adhesion 
molecules in inflammatory myopathies: diagnostic utility and pathogenetic insights. 
Folia neuropathologica / Association of Polish Neuropathologists and Medical 
Research Centre, Polish Academy of Sciences. 2009; 47(1):33-42. 
106. Lundberg I, Kratz AK, Alexanderson H, et al. Decreased expression of 
interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue 
   43 
following corticosteroid treatment in patients with polymyositis and dermatomyositis. 
Arthritis Rheum. 2000 Feb; 43(2):336-348. 
107. Khanapure SP, Garvey DS, Janero DR, et al. Eicosanoids in 
inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Current topics in 
medicinal chemistry. 2007; 7(3):311-340. 
108. Spector AA. Arachidonic acid cytochrome P450 epoxygenase pathway. 
Journal of lipid research. 2009 Apr; 50 Suppl:S52-56. 
109. Kudo I, Murakami M. Phospholipase A2 enzymes. Prostaglandins & 
other lipid mediators. 2002 Aug; 68-69:3-58. 
110. Murakami M, Kudo I. Recent advances in molecular biology and 
physiology of the prostaglandin E2-biosynthetic pathway. Progress in lipid research. 
2004 Jan; 43(1):3-35. 
111. Sandig H, Pease JE, Sabroe I. Contrary prostaglandins: the opposing roles 
of PGD2 and its metabolites in leukocyte function. Journal of leukocyte biology. 2007 
Feb; 81(2):372-382. 
112. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. 
Arteriosclerosis, thrombosis, and vascular biology. 2011 May; 31(5):986-1000. 
113. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of 
inflammation and immune responses by prostaglandins and thromboxanes. The Journal 
of clinical investigation. 2001 Jul; 108(1):15-23. 
114. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-
inflammatory drugs. Am J Med. 1998 Mar 30; 104(3A):2S-8S; discussion 21S-22S. 
115. Sellers RS, Radi ZA, Khan NK. Pathophysiology of cyclooxygenases in 
cardiovascular homeostasis. Veterinary pathology. 2010 Jul; 47(4):601-613. 
116. Murakami M, Naraba H, Tanioka T, et al. Regulation of prostaglandin E2 
biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in 
concert with cyclooxygenase-2. J Biol Chem. 2000 Oct 20; 275(42):32783-32792. 
117. Hara S, Kamei D, Sasaki Y, et al. Prostaglandin E synthases: 
Understanding their pathophysiological roles through mouse genetic models. 
Biochimie. 2010 Jun; 92(6):651-659. 
118. Kalinski P. Regulation of immune responses by prostaglandin E2. J 
Immunol. 2012 Jan 1; 188(1):21-28. 
119. Coleman RA, Smith WL, Narumiya S. International Union of 
Pharmacology Classification of Prostanoid Receptors - Properties, Distribution, and 
Structure of the Receptors and Their Subtypes. Pharmacol Rev. 1994 Jun; 46(2):205-
229. 
120. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: Structures, 
properties, and functions. Physiol Rev. 1999 Oct; 79(4):1193-1226. 
121. Matsuoka T, Narumiya S. Prostaglandin receptor signaling in disease. 
Thescientificworldjo. 2007; 7:1329-1347. 
122. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 2007 
Apr 20; 282(16):11613-11617. 
123. Baracos V, Rodemann HP, Dinarello CA, et al. Stimulation of muscle 
protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). 
A mechanism for the increased degradation of muscle proteins during fever. The New 
England journal of medicine. 1983 Mar 10; 308(10):553-558. 
124. Schafers M, Sorkin LS, Sommer C. Intramuscular injection of tumor 
necrosis factor-alpha induces muscle hyperalgesia in rats. Pain. 2003 Aug; 104(3):579-
588. 
125. Rodemann HP, Goldberg AL. Arachidonic acid, prostaglandin E2 and F2 
alpha influence rates of protein turnover in skeletal and cardiac muscle. J Biol Chem. 
1982 Feb 25; 257(4):1632-1638. 
 44 
126. Zalin RJ. The role of hormones and prostanoids in the in vitro 
proliferation and differentiation of human myoblasts. Experimental cell research. 1987 
Oct; 172(2):265-281. 
127. Otis JS, Burkholder TJ, Pavlath GK. Stretch-induced myoblast 
proliferation is dependent on the COX2 pathway. Experimental cell research. 2005 
Nov 1; 310(2):417-425. 
128. Studynkova JT, Kuchen S, Jeisy E, et al. The expression of 
cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle 
tissue of patients with polymyositis and dermatomyositis. Clinical and experimental 
rheumatology. 2004 Jul-Aug; 22(4):395-402. 
129. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E 
synthase-1: a novel therapeutic target. Pharmacological reviews. 2007 Sep; 59(3):207-
224. 
130. Samuelsson B, Haeggstrom JZ, Wetterholm A. Leukotriene Biosynthesis. 
Annals of the New York Academy of Sciences. 1991 Jul 31; 629:89-99. 
131. Peters-Golden M, Brock TG. 5-lipoxygenase and FLAP. Prostag Leukotr 
Ess. 2003 Aug-Sep; 69(2-3):99-109. 
132. Bell RL, Harris RR. The enzymology and pharmacology of 5-
lipoxygenase and 5-lipoxygenase activating protein. Clin Rev Allerg Immu. 1999 Spr-
Sum; 17(1-2):91-109. 
133. Borgeat P, Naccache PH. Biosynthesis and Biological-Activity of 
Leukotriene-B4. Clin Biochem. 1990 Oct; 23(5):459-468. 
134. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B-4 receptors. 
Prostag Leukotr Ess. 2003 Aug-Sep; 69(2-3):123-134. 
135. Hedenberg-Magnusson B, Ernberg M, Alstergren P, et al. Pain mediation 
by prostaglandin E2 and leukotriene B4 in the human masseter muscle. Acta Odontol 
Scand. 2001 Dec; 59(6):348-355. 
136. Hedenberg-Magnusson B, Ernberg M, Alstergren P, et al. Effect on 
prostaglandin E2 and leukotriene B4 levels by local administration of glucocorticoid in 
human masseter muscle myalgia. Acta Odontol Scand. 2002 Jan; 60(1):29-36. 
137. Studynkova JT, Kuchen S, Jeisy E, et al. The expression of 
cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle 
tissue of patients with polymyositis and dermatomyositis. Clinical & Experimental 
Rheumatology. 2004; 22(4):395-402. 
138. Sun R, Ba X, Cui L, et al. Leukotriene B4 regulates proliferation and 
differentiation of cultured rat myoblasts via the BLT1 pathway. Molecules and Cells. 
2009; 27(4):403-408. 
139. Pette D, Staron RS. Molecular basis of the phenotypic characteristics of 
mammalian muscle fibres. Ciba Foundation Sypmosium. 1988; 188:22-34. 
140. Bassel-Duby R, Olson EN. Signaling pathways in skeletal muscle 
remodeling. Annual Review of Biochemistry. 2006(75):19-37. 
141. Staron RS, Hagerman FC, Hikida RS, et al. Fiber type composition of the 
vastus lateralis muscle of young men and women. Journal of Histochemistry & 
Cytochemistry. 2000 May; 48(5):623-629. 
142. Martini F. Fundamentals of Anatomy & Physiology. 6th ed. San 
Fransisco: Pearson Education Inc, 2004. 
143. McArdle W. Exercise Physiology, Energy, Nutrition and Human 
Performance. 5th ed. Baltimore: Lippincott WIlliams & Wilkins, 2001. 
144. Allen DG, Lamb GD, Westerblad H. Skeletal muscle fatigue: Cellular 
mechanisms. Physiol Rev. 2008 Jan; 88(1):287-332. 
   45 
145. Keyser RE. Peripheral fatigue: high-energy phosphates and hydrogen 
ions. PM & R : the journal of injury, function, and rehabilitation. 2010 May; 2(5):347-
358. 
146. Pette D, Staron RS. Cellular and molecular diversities of mammalian 
skeletal muscle fibers. Reviews of physiology, biochemistry and pharmacology. 1990; 
116:1-76. 
147. Yuan Y, Shi XE, Liu YG, et al. FoxO1 regulates muscle fiber-type 
specification and inhibits calcineurin signaling during C2C12 myoblast differentiation. 
Molecular and cellular biochemistry. 2011 Feb; 348(1-2):77-87. 
148. Towle HC. Glucose as a regulator of eukaryotic gene transcription. 
Trends Endocrin Met. 2005 Dec; 16(10):489-494. 
149. Dastmalchi M, Alexanderson H, Loell I, et al. Effect of physical training 
on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated 
mechanism for muscle impairment in polymyositis or dermatomyositis. Arthrit Rheum-
Arthr. 2007 Oct 15; 57(7):1303-1310. 
150. Scola RH, Werneck LC, Prevedello DM, et al. Diagnosis of 
dermatomyositis and polymyositis: a study of 102 cases. Arq Neuropsiquiatr. 2000; 
58(3B):789-799. 
151. Hilário MO, Yamashita H, Lutt iD, et al. Juvenile idiopathic 
inflammatory myopathies: the value of magnetic resonance imaging in the detection of 
muscle involvement. Sao Paulo Med J. 2000; 2(118):35-40. 
152. Bodinefowler S. Skeletal-Muscle Regeneration after Injury - an 
Overview. J Voice. 1994 Mar; 8(1):53-62. 
153. Grounds MD. Age-associated changes in the response of skeletal muscle 
cells to exercise and regeneration. Towards Prolongation of the Healthy Life Span. 
1998; 854:78-91. 
154. Charge SBP, Rudnicki MA. Cellular and molecular regulation of muscle 
regeneration. Physiol Rev. 2004 Jan; 84(1):209-238. 
155. Necela BM, Cidlowski JA. Mechanisms of glucocorticoid receptor action 
in noninflammatory and inflammatory cells. Proceedings of the American Thoracic 
Society. 2004; 1(3):239-246. 
156. Hayashi R, Wada H, Ito K, et al. Effects of glucocorticoids on gene 
transcription. Eur J Pharmacol. 2004 Oct 1; 500(1-3):51-62. 
157. Newton R, Holden NS. Separating transrepression and transactivation: A 
distressing divorce for the glucocorticoid receptor? Mol Pharmacol. 2007 Oct; 
72(4):799-809. 
158. Strehl C, Spies CM, Buttgereit F. Pharmacodynamics of glucocorticoids. 
Clinical and experimental rheumatology. 2011 Sep-Oct; 29(5 Suppl 68):S13-18. 
159. Croxtall JD, Choudhary Q, Flower RJ. Glucocorticoids act within 
minutes to inhibit recruitment of signalling factors to activated EGF receptors through a 
receptor-dependent, transcription-independent mechanism. Brit J Pharmacol. 2000 
May; 130(2):289-298. 
160. Bartholome B, Spies CM, Gaber T, et al. Membrane glucocorticoid 
receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells 
and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. 
Faseb J. 2004 Jan; 18(1):70-80. 
161. Stahn C, Buttgereit F. Genomic and nongenomic effects of 
glucocorticoids. Nat Clin Pract Rheum. 2008 Oct; 4(10):525-533. 
162. Carpinteri R, Porcelli T, Mejia C, et al. Glucocorticoid-induced 
osteoporosis and parathyroid hormone. Journal of endocrinological investigation. 
2010; 33(7 Suppl):16-21. 
 46 
163. Ong SLH, Whitworth JA. How Do Glucocorticoids Cause Hypertension: 
Role of Nitric Oxide Deficiency, Oxidative Stress, and Eicosanoids. Endocrin Metab 
Clin. 2011 Jun; 40(2):393-+. 
164. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-
induced myopathy. J Endocrinol. 2008 Apr; 197(1):1-10. 
165. Minetto MA, Lanfranco F, Motta G, et al. Steroid myopathy: Some 
unresolved issues. Journal of endocrinological investigation. 2011 May; 34(5):370-
375. 
166. Bandelier C, Guerne PA, Genevay S, et al. Clinical experience with 
mycophenolate mofetil in systemic autoimmune conditions refractory to common 
immunosuppressive therapies. Swiss medical weekly. 2009 Jan 24; 139(3-4):41-46. 
167. Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for 
interstitial lung disease in dermatomyositis. Arthritis care & research. 2010 Oct; 
62(10):1496-1501. 
168. Helmers SB, Dastmalchi M, Alexanderson H, et al. Limited effects of 
high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in 
muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis. 2007 Oct; 
66(10):1276-1283. 
169. Fernandez RR, Rubio JLC, Cano DS, et al. Rituximab in the treatment of 
dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of 
the literature. Clinical and experimental rheumatology. 2009 Nov-Dec; 27(6):1009-
1016. 
170. Cambridge G, Leandro MJ, Edwards JCW, et al. Serologic changes 
following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 
2003 Aug; 48(8):2146-2154. 
171. Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab Therapy for 
Myopathy Associated With Anti-Signal Recognition Particle Antibodies: A Case 
Series. Arthritis care & research. 2010 Sep; 62(9):1328-1334. 
172. Zong M MV, Lundberg IE. Anakinra Effects on T Cells in Patients with 
Rrefractory Idiopathic Inflammatory Myopathies Annals Rheum Dis. 2011; 70(2). 
173. Dastmalchi M, Alexanderson H, Loell I, et al. Effect of physical training 
on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated 
mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis 
Rheum. 2007 Oct 15; 57(7):1303-1310. 
174. Alexanderson H, Stenstrom CH, Jenner G, et al. The safety of a resistive 
home exercise program in patients with recent onset active polymyositis or 
dermatomyositis. Scand J Rheumatol. 2000; 29(5):295-301. 
175. Alexanderson H, Dastmalchi M, Esbjornsson-Liljedahl M, et al. Benefits 
of intensive resistance training in patients with chronic polymyositis or 
dermatomyositis. Arthritis Rheum. 2007 Jun 15; 57(5):768-777. 
176. Nader GA, Dastmalchi M, Alexanderson H, et al. A Longitudinal, 
Integrated, Clinical, Histological and mRNA Profiling Study of Resistance Exercise in 
Myositis. Mol Med. 2010 Nov-Dec; 16(11-12):455-464. 
177. Chung YL, Alexanderson H, Pipitone N, et al. Creatine supplements in 
patients with idiopathic inflammatory myopathies who are clinically weak after 
conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-
controlled trial. Arthritis Rheum. 2007 May 15; 57(4):694-702. 
178. Vella L, Caldow MK, Larsen AE, et al. Resistance exercise increases NF-
kappaB activity in human skeletal muscle. American journal of physiology Regulatory, 
integrative and comparative physiology. 2012 Mar; 302(6):R667-673. 
   47 
179. Dorph C, Nennesmo I, Lundberg IE. Percutaneous conchotome muscle 
biopsy. A useful diagnostic and assessment tool. The Journal of rheumatology. 2001 
Jul; 28(7):1591-1599. 
180. Dietrichson P, Coakley J, Smith PE, et al. Conchotome and needle 
percutaneous biopsy of skeletal muscle. Journal of neurology, neurosurgery, and 
psychiatry. 1987 Nov; 50(11):1461-1467. 
181. Targoff IN. Laboratory testing in the diagnosis and management of 
idiopathic inflammatory myopathies. Rheumatic diseases clinics of North America. 
2002 Nov; 28(4):859-890, viii. 
182. Rider LG, Miller FW. Laboratory evaluation of the inflammatory 
myopathies. Clinical and diagnostic laboratory immunology. 1995 Jan; 2(1):1-9. 
183. Josefson A, Romanus E, Carlsson J. A functional index in myositis. The 
Journal of rheumatology. 1996 Aug; 23(8):1380-1384. 
184. Alexanderson H, Broman L, Tollback A, et al. Functional index-2: 
Validity and reliability of a disease-specific measure of impairment in patients with 
polymyositis and dermatomyositis. Arthritis Rheum. 2006 Feb 15; 55(1):114-122. 
185. Rider LG, Koziol D, Giannini EH, et al. Validation of manual muscle 
testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory 
myopathies. Arthritis care & research. 2010 Apr; 62(4):465-472. 
186. Sugiura T, Kawaguchi Y, Harigai M, et al. Increased IL-15 production in 
muscle cells of polymyositis/dermatomyositis. Arthritis and Rheumatism. 1999 Sep; 
42(9):S158-S158. 
187. Khan KMF, Kothari P, Du BH, et al. Matrix Metalloproteinase-
Dependent Microsomal Prostaglandin E Synthase-1 Expression in Macrophages: Role 
of TNF-alpha and the EP4 Prostanoid Receptor. Journal of Immunology. 2012 Feb 15; 
188(4):1970-1980. 
188. Maxis K, Delalandre A, Martel-Pelletier J, et al. The shunt from the 
cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral 
osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating 
protein. Arthritis research & therapy. 2006; 8(6):R181. 
189. Boulet L, Ouellet M, Bateman KP, et al. Deletion of microsomal 
prostaglandin E-2 (PGE(2)) synthase-1 reduces inducible and basal PGE(2) production 
and alters the gastric prostanoid profile. J Biol Chem. 2004 May 28; 279(22):23229-
23237. 
190. Dieter P, Scheibe R, Jakobsson PJ, et al. Functional coupling of 
cyclooxygenase 1 and 2 to discrete prostanoid synthases in liver macrophages. 
Biochemical and biophysical research communications. 2000 Sep 24; 276(2):488-492. 
191. Guerrero MD, Aquino M, Bruno I, et al. Synthesis and pharmacological 
evaluation of a selected library of new potential anti-inflammatory agents bearing the 
gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production 
through the selective modulation of microsomal prostaglandin E synthase-1 expression. 
J Med Chem. 2007 May 3; 50(9):2176-2184. 
192. Bruno A, Di Francesco L, Coletta I, et al. Effects of AF3442 [N-(9-ethyl-
9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human 
microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human 
monocytes in vitro. Biochem Pharmacol. 2010 Apr 1; 79(7):974-981. 
193. Mbalaviele G, Pauley AM, Shaffer AF, et al. Distinction of microsomal 
prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in 
cells using a novel, selective mPGES-1 inhibitor. Biochem Pharmacol. 2010 May 15; 
79(10):1445-1454. 
194. Harizi H, Juzan M, Moreau JF, et al. Prostaglandins inhibit 5-
lipoxygenase-activating protein expression and leukotriene B-4 production from 
 48 
dendritic cells via an IL-10-dependent mechanism. Journal of Immunology. 2003 Jan 1; 
170(1):139-146. 
195. Zhai BB, Yang HQ, Mancini A, et al. Leukotriene B-4 BLT Receptor 
Signaling Regulates the Level and Stability of Cyclooxygenase-2 (COX-2) mRNA 
through Restricted Activation of Ras/Raf/ERK/p42 AUF1 Pathway. J Biol Chem. 2010 
Jul 30; 285(31):23568-23580. 
196. Alexanderson H. Exercise effects in patients with adult idiopathic 
inflammatory myopathies. Current opinion in rheumatology. 2009 Mar; 21(2):158-163. 
197. Sultan SM, Ioannou Y, Moss K, et al. Outcome in patients with 
idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford). 
2002 Jan; 41(1):22-26. 
198. Hawke TJ, Kanatous SB, Martin CM, et al. Rad is temporally regulated 
within myogenic progenitor cells during skeletal muscle regeneration. Am J Physiol-
Cell Ph. 2006 Feb; 290(2):C379-C387. 
199. Fisher I, Abraham D, Bouri K, et al. Prednisolone-induced changes in 
dystrophic skeletal muscle. Faseb J. 2005 May; 19(7):834-836. 
200. Norman H, Nordquist J, Andersson P, et al. Impact of post-synaptic block 
of neuromuscular transmission, muscle unloading and mechanical ventilation on 
skeletal muscle protein and mRNA expression. Pflug Arch Eur J Phy. 2006 Oct; 
453(1):53-66. 
 
 
